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Formalism and the Legal Status of Body Parts
Michele Goodwint
Our function cannot be limited to a mere blind adherence to
precedent. We must determine with the best exercise of our
mental powers of which we are capable that law which in all
probability will be applied ... If this means the discovering
and applying of a "new doctrinal trend" ... this is our task to
be performed directly and straightforwardly, rather than
"artfully" dodged.1
INTRODUCTION
This article addresses a narrow aspect of the body commodi-
fication debate, specifically the remedy for nonconsensual appro-
priation of human body parts, including tissues, bones, heart
valves, and other substances unique in value to the human body.
The answer to whether there is a remedy for the malfeasance of
"stealing" a body part, however, depends upon how we legally
conceptualize the body and rights associated with it. Is it prop-
erty, a product, our mere possession (a borrowed vessel belonging
to the state or god), or a service? Each of these terms embodies
social values and legal statuses, both of which are significant to
judicial interpretation.
t Professor of Law and Director of the Health Law Institute at DePaul University
College of Law. I would like to thank June Carbone, Martha Ertman, Stephen Siegel,
Stephan Landsman, Dorothy Roberts and Andrew Gold for discussing these ideas with
me. This article is an attempt to push the discourse on commodification beyond its imme-
diate perimeters and to think more deeply about the legal and social status of the body
and how our interpretations on this question impact biotechnology and legal claims on
the micro and macro levels. This is a first attempt to stumble through the woods on par-
ticular status questions and to create a clearing where others may venture to debate. I
am grateful for the dedicated research assistance provided by Erin Crow. I am also grate-
ful to Basil Cherian, Mark Premo-Hopkins, and their colleagues at the University of
Chicago Legal Forum.
S pector Motor Service v Walsh, 139 F2d 809, 814 (2d Cir 1943). See also Benjamin
Cardozo, The Growth of The Law 56-80 (1924) (charting the evolution of decisionmaking
from pure adherence to precedent to a less rigid and more flexible approach commonly
associated with shift from naturalism to pragmatism).
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If the body were to be redefined as property, it would violate
the established normative view of the body as a sacred, inalien-
able object.2 For some the question posed might be a false one-
the property interest they might suggest is not in the body itself,
but in the right to the body. Yet this layer of abstraction, while
certainly convenient for my perspective, is yet a matter of obfus-
cation from the question itself, which technology demands that
we answer. Equally, without a legal status the body is also vul-
nerable to the unremedied exploitation of others. 3 Thus, as prop-
erty, a legitimate claim of ownership can be made, and the abil-
ity to redress nonconsensual appropriation is better established.4
If the body exists only for the purpose of carrying our souls and it
is violated, it would seem that whatever cause of action that
might exist is not one to be adjudicated in courts of law.
A determination of whether the body is property might in-
fluence the outcome of several cases currently in litigation, in-
cluding whether heart valves and tissues used for donation are
products, whether universities have a property claim or proprie-
tary interest in research subjects' DNA and tissues, the constitu-
tionality of body part conscription laws, and whether causes of
action can be sustained for wrongful implantation, directed im-
plantation, and likely a host of other foreseeable and also uni-
maginable problems. This determination will be a significant
factor in future product liability claims, including Miller v Hart-
ford Hospital, a case involving the implantation of contaminated
heart valve tissue, which is in the initial stages of litigation in
Connecticut,' the final disposition of Martin v Young Kim,7 now
in district court litigation in Indiana, and likely many more.
2 See Margaret Jane Radin, Market-Inalienability, 100 Harv L Rev 1849, 1851
(1987) ("In conceiving of all rights as property rights that can (at least theoretically) be
alienated in markets, economic analysis has ... invited us to view all inalienabilities as
problematic.").
3 See, for example, Judith D. Fischer, Misappropriation of Human Eggs and Em-
bryos and the Tort of Conversion: A Relational View, 32 Loyola LA L Rev 381, 381 (1999)
(noting that "[a]s technological breakthroughs change the world, old legal theories may
seem inadequate to address new legal problems").
4 Id at 402-03 (advocating a torts conversion remedy for patient-victims in order to
make them whole again).
5 40 Conn L Rptr 508 (Superior Ct Conn 2005).
6 See, for example, Human Aorta Valve May Qualify as Product, Ct Law Trib 33
(Jan 9, 2006) (discussing the suit against doctors and Cryolife, alleging medical malprac-
tice, wrongful death and products liability based on the death of Leonard Klein who re-
ceived a heart valve in a transplant that was allegedly infected with fungus).
7 See Martin v Young Kim, 2005 US Dist LEXIS 20595 (N D Ind 2005) (where a
young man was killed and the parents wished to have his kidney donated to his uncle,
but were denied because the coroner determined an autopsy would be necessary render-
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Anticommodification scholars wouid be right to suggest. lt
we transgress, to some extent, established ethical norms and set-
tled law by introducing financial considerations to the body.' A
central tenet in contemporary biotechnology jurisprudence ex-
empts the body from being tangible "property."' Yet, such per-
spectives are also ahistorical-not of the brutality found in sev-
enteenth to nineteenth century slavery in the United States-but
of our immediate past and predictable future. To be sure, we may
not like discussing the human body in market-like terms, with
values and assessments. However, market realities in the body
already exist1" and our failure to recognize this has its own set of
consequences, including a sorely lacking and undeveloped no-
menclature, the exploitation of human subjects, 1 a loosely moni-
tored but robust market in buying and selling purloined human
tissues," and an expanding, conflicting common law. 3 The rapid
ing the kidneys unavailable, the court held the claim survived summary judgment be-
cause Indiana case law supported a property right in a deceased family member).
8 Consider Radin, 100 Harv L Rev at 1851 (cited in note 2) (asserting that "the char-
acteristic rhetoric of economic analysis is morally wrong when it is put forward as the sole
discourse of human life").
9 See, for example, Shults v United States, 995 F Supp 1270, 1275-76 (D Kan 1998)
(holding that parents of a deceased airman had no claim for conversion where portions of
their son's tissues and organs were discarded after autopsy); Perry v St Francis Hosp and
Med Ctr, 886 F Supp 1551, 1553 (D Kan 1995) (denying recovery for breach of contract
based on the defendant's removal of more body parts than were authorized); Bauer v
North Fulton Med Ctr, 527 SE2d 240, 244 (Ga Ct App 1999) (concluding that a widow
could not maintain a claim for conversion based on the unauthorized removal of her hus-
band's eye tissue); Moore v Regents of University of California, 793 P2d 479 (Cal 1990)
(denying conversion claim of patient whose tissues had been nonconsensually tested,
conveyed to third parties, and patented); Hasselbach v Mt Sinai Hosp, 173 AD 89, 92 (1st
Dept NY 1916) (opining that a widow could not maintain a conversion claim for an unau-
thorized autopsy performed on her husband). See also Richard Gold, Owning Our Bodies:
An Examination of Property Law and Biotechnology, 32 San Diego L Rev 1167, 1171
(1995) ("The human body and its component parts are not, however, market goods.")
10 Medical researchers, for example, partake in the market of human tissues when
they obtain authorization for medical tests and samples that later result in patenting of
cell lines or other similar financially beneficial medical products. See, for example, Donna
Dickenson, Consent, Commodification and Benefit-Sharing in Genetic Research, 4(2)
Developing World Bioethics 109 (2004) (focusing on disadvantaged populations both in
the developing world and First World countries). In addition, a rather robust market in
human eggs exists and is well-publicized and documented. See, for example, Kenneth
Baum, Golden Eggs: Towards the Rational Regulation of Oocyte Donation, 2001 BYU L
Rev 107, 107-112 (2001) (discussing an infertile couple's solicitation of female students
attending prestigious universities for oocyte donation and a website advertising auctions
for oocytes and sperm, and documenting the resulting media coverage).
11 For a thorough discussion of exploitation of disadvantaged populations in medical
research, consider Dickenson, 4(2) Developing World Bioethics 109 (cited in note 10).
12 The most recent purloined tissue incident occurred in New York. Robert Smith,
Four Indicted in Case of Tissue Theft, National Public Radio, (Feb 23, 2006) available at
<httDJ/www.nvr.orgltemplates/story/story.php?storyId=5230544> (last visited May 4,
2006).
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growth of biotechnology has produced overwhelming demand and
uses for human body parts.14 Body parts now captured for bio-
technological purposes were once considered human waste and
were thus discarded by doctors, hospitals, and clinics.' 5 Yet, to-
day there is a market in body parts-and physicians, hospitals,
and patients have come to rely on their availability. How human
substances are acquired may be more troubling than the fact
that a black market exists. Acquisition occurs through such
means as coercion and fraud (in other words, tissues donated for
altruistic purposes, but later sold by the donees),' s funeral homes
and crematoriums desecrating and selling body parts, 7 and mis-
appropriation from some physicians, scientists, and research-
ers. 1
8
13 Even the state of the law governing the transfers of human eggs (a rather common
occurrence among couples facing infertility) is conflicting. For a discussion of this conflict
see Baum, 2001 BYU L Rev at 123-34 (cited in note 10).
14 Office of Technology Assessment, United States Congress, Ownership ofHuman
Tissues and Cells: New Developments in Biotechnology 23 (Books for Business 2001):
Over the past decade, however, technological advances have resulted in new,
enhanced methods for studying and using human body parts-particularly tis-
sues and cells .... Human samples are not only an integral part of the biomedi-
cal research process, but they are now also used as a component of (or in the
production of) a variety of commercial products ranging from drugs and vaccines
to pregnancy test kits.
Id.
15 One of the seminal cases regarding pecuniary gain from material otherwise consid-
ered to be medical waste occurred in 1990. Moore v Regents of The University of Califor-
nia, 793 P2d 479 (Cal 1990). A leukemia patient underwent treatment at UCLA's Medical
Center. After removing the patient's spleen as part of his treatment, one of the doctors
who treated the patient used his cells to develop and patent a profitable cell line. Id at
480-82.
16 See Michele Goodwin, Commerce in Cadavers is an Open Secret, LA Times B15
(Mar 11, 2004) (discussing litigation in state and federal courts involving the black mar-
ket sale of body parts taken from cadavers donated by family members); Charles Ornstein
and Monte Morin, UC Got Body Parts Warning a Year Ago, LA Times Al (Mar 16, 2004)
(discussing the alleged black market sales of donated cadavers by UCLA employees).
17 Jeff Nesmith, Funeral Home Thets: Body Parts May Be Tainted-Patients Tested
as 2'pple of Fear' Reaches Atlanta, The Atlanta Journal-Constitution Al (April 23,
2006); Paul Harris, They Replaced Stolen Bones With !ipes: Organs With Rags-1077
Corpses Carved Up By Illegal Body Snatchers Who Sold Their 'Harves' On The Donor
Market, The Observer (England) 20 (April 2, 2006). See also Jackson v Biomedical 7'ssue
Servs Ltd, No 06-CV-1323 (D NJ complaint filed Mar 30, 2006) (plaintiff alleging that
hepatitis was contracted through purloined body parts sold in the donor market).
18 See Moore, 793 P2d at 480-81 (involving a UCLA Medical Center physician who
concealed from his patient that additional cells were being removed from the patient in
order to conduct profitable research); Dickenson, 4(2) Developing World Bioethics at 110
(cited in note 10) (discussing one researcher's misrepresentation to a certain population in
New Guinea that she wanted blood samples to check for insects, when she actually
wanted the samples to enhance research in pursuit of a patent, and another set of re-
searcher's misrepresentations to Chinese villagers that they would receive medical care
in exchange for DNA samples).
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Nevertheless, some scholars conclude that to place a finan-
cial value on the body is to diminish its personhood and pollute
our otherwise homogeneous understanding of its legal, social,
and moral status.19 To formalists, the human body is a sacred
entity, and its status as such is violated by any associations with
financial evaluations and market terms and conditions." An ex-
trapolation of this theory is that the body should remain an inal-
ienable vessel, without regard to the uses governments and pri-
vate entities find for it, lawful or not.21 Legal and social commen-
tators invoke the horrific slave experience in the United States to
buttress their claim and to demonstrate in graspable, stark
terms the significant consequences of placing financial value on
human beings.22 To suggest that their arguments are dated in-
vites remonstration from varied ideological corners wedded to
the anticommodification, incommensurability perspective. Their
reasons for avoiding what I believe are overdue dialogues about
what ultimately involves the reach of biotechnology into our per-
sonal spheres are not altogether difficult to understand, even if
slightly overstated.
These are the new formalists-or formalists just on the point
of body parts. They reject or ignore the evolving nuances of body
parts with respect to law and biotechnology.23 Typically, they
19 Consider Radin, 100 Harv L Rev at 1865 (cited in note 2) (arguing that economic
analysis is morally wrong when applied to the human body).
20 Id.
21 Id.
22 Ronald Arnold, et a, Financial Incentives for Cadaver Organ Donation: An Ethical
Reappraisal, 73 Transplantation 1361, 1366 (2002) ("It is also important to note that our
society does not permit its capitalistic system to operate in certain commodified ex-
changes because they are considered to be intrinsically wrong.").
2 Legal formalists typically regard legal texts, such as statutes, regulations, the
Constitution, and prior precedent as the basis of, and usually the exclusive foundation
for, judicial opinions. At its epicenter, formalism embraces the concept that law is created
by the state and its agencies and the legal rules that result from the legislature's delib-
erations are the state's imperative. Formalists argue that the judiciary is restrained by
the separation of powers to reach beyond legal texts and their plain meaning. Their role
is to determine what the law is and not what the law should be. To infuse the law with
their social and political sympathies would undermine the rule of law.
The new formalists are unlike traditional formalists-and in fact they may be
formalists only on the subject of the body itself. Ironically, the new formalists would have
very little in common with their more traditional counterparts. Indeed, they are likely to
be critics of the conventional formalists.
The traditional formalists are considered rigid and constrained in their thinking;
limited in their willingness to view the law as an evolving set of principles. See Guido
Calabresi, An Introduction to Legal Thought: Four Approaches to Law and to the Alloca-
tion of Body Parts, 55 Stan L Rev 2113, 2115-16 (2003) (describing a range of inherent
conservatism in traditional formalist thinking). Rather, the old formalists "speak of law
as a science. with its own Drinciples, processes of reasoning, and discoverable facts." Id at
2115 n 4.
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might have nothing in common with those considered to be the
traditional formalists, hewn from a more conservative under-
standing of the law and what the rule of law should be. They are
not necessarily "right wing" or neoconservatives; their values are
rooted in the "cause" behind their scholarship.24 No, the new for-
malists might consider themselves even radical within their own
discourses.
For example, feminist legal theorists often critique market-
based body valuation as a form of sexual exploitation and op-
pression of women.25 To these theorists, deliberation on the body
in market terms reifies the subordinate status of women in soci-
ety and vertical power relationships. Others may find the race-
sensitive dialogue of slavery altogether uncomfortable and thus
avoid the broader debate about body parts.27 Scholars of Critical
Race Theory may be loath to venture down the politically un-
popular terrain of body part commodification, simply opposed as
a de facto position, or perhaps they believe there are other, far
more important legal issues with which to contend.28 Those
within the liberal left concerned about politically appropriate
critique may wish to consider the validity of incommensurability
claims, but only if other valued constituencies within the acad-
emy are not offended. Antimarket conservatives equally disap-
prove of valuations placed on human biological resources, but for
different reasons than those speculated above. Their concerns
24 Id at 2116.
25 Consider Catharine A. MacKinnon, Toward a Feminist Theory of the State 3-12
(Harvard 1989); Naomi Wolf, The Beauty Myth: How Images of Beauty Are Used Against
Women (Perennial 2002) (arguing the "wealth" women possess via their beauty is illu-
sory, and actually a form of social and political oppression). Wolf discusses what she
called the "professional beauty qualification" as a "condition for women's hiring and pro-
motion." Id at 27.
26 Andrea Dworkin, Pornography: Men Possessing Women 14-18, 53-56 (E.P. Dutton
1989).
27 See, for example, Alice M. Noble-Allgire, In Pursuit of Justice Powell's Vision:
Diversity-Conscious Admissions is Just the First Step, 14 Berkeley La Raza L J 255, 257-
59 (2003) (illustrating a scenario where two law professors avoid discussing relevant
racial issues, and suggesting that this country cannot be color blind as some would sug-
gest without avoiding other necessary discourse). The thought that we can be color blind
induces individuals who avoid the issue of race completely to feel as if "African Americans
should 'not belabor the question of what happened in the past.'" Id at 259.
28 Not all Critical Race Theorists, however, have avoided the issue of body commodi-
fication. See, for example, Khiara M. Bridges, Note, On the Commodification of the Black
Female Body: The Critical Implications of the Alienability of Fetal 7Yssue, 102 Colum L
Rev 123 (2002). Bridges' Note "explores the question ... [of what impact] a market in fetal
tissue will have on Black women [from a Critical Race Theory perspective]." Id at 123.
Bridges "concludes that because Black women will be disproportionately exploited, as
well as disenfranchised from the benefits produced by a market in fetal tissue, fetal tissue
should not be made market alienable." Id.
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are often grounded in the abortion debate, 9 religious terms,a3
and moral claims (not to suggest that these considerations are
not important on some level to the others). There are some schol-
ars in other schools of thought who may equally reject the notion
of property in the body, including the doctrinalists and formal-
ists, whose devoted following of precedent (judicial or legislative)
indicates an inflexibility to the introduction of exogenous values
(in other words, if the law never granted such status to the body,
why do it now?).31
Ultimately, the fear to speculate and even contemplate the
body in any legal terms other than our late nineteenth century
understanding, based on the possibility we will cross into the
bounds of slavery or for the love of stare decisis, limits the poten-
tial for robust, informed, meaningful contemporary dialogue and
debate on a critical topic of our times. 2 Furthermore, this appre-
hension undermines scholars' ability to credibly engage in policy
debates on the reach and normative positioning of biotechnology
within the law. Biotechnology can, will, and has run amok amid
this indeterminacy. Such fears might actively serve to deflect
race issues, but in doing so, also lead to the avoidance of substan-
tive investigation and analysis of markets that already exist and
affect racialized bodies.
Therefore, that biotechnology outpaces legal response, in-
cluding the development of regulation and meaningful social pol-
icy (that could be attentive to racial, gender, and cultural issues)
should not come as a surprise. Nor is it a revelation that courts
seem unprepared in their review of modern cases dealing with
29 See Maxwell J. Mehlman, The Story of Moore v Regents of the University of Cali-
fornia, in Gerald Korngold and Andrew P. Morriss, eds, Property Stories 49 (Foundation
2004) ("[C]onservatives worry that commodifying the body would weaken opposition to
abortion and to fetal embryo experimentation.").
30 Stephen Wilkinson, Bodies for Sale: Ethics and Exploitation in the Human Body
Trade 210-11 (Routledge 2003) (Members of the Southern Baptist Convention's Christian
Life Committee argue against the commodification of human DNA patents: "any gene
that belongs to the human genome [is] ... sacred. Furthermore, all life, as created by God
and thus a gift of God, has intrinsic value.").
31 See Calabresi, 55 Stan L Rev at 2114-15 (cited in note 23) (discussing the tradi-
tional formalist tendency to focus on rules as they exist in the status quo). Calabresi
describes formalism (and doctrinalism) as "enjoying something of a renaissance." Id at
2114. Calabresi further describes both formalism and doctrinalism as viewing the "law as
autonomous and distinct from other fields of learning." Id at 2115.
Legal analysis, under this approach, at least in its pure form, can be carried out
without reference to other disciplines or other sources of values. The principal job of such
analysis is to render the rules of law consistent and coherent with each other, so that like
cases are treated alike. Id.
32 See, for example, Wilkinson, Bodies For Sale at 136, 174, 207-09 (cited in note 30)
(comparing paid surrogacy, DNA patenting and slavery).
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these issues.33 The judicial opinions that result from months of
pondering the legitimacy of aggrieved plaintiffs' claims or pleas
for injunctions often reflect that ambivalence and result in judi-
cial formalism.34 Meaningful public policy about the use and
value of stem cells, organ transplantation, cloning, pre-
implantation genetic diagnosis, and xenotransplantation cannot
(and should not) be developed in a vacuum.
Part I of the Article considers what a deprivation in the con-
text of the human body actually means to our nascent jurispru-
dence in this domain. That is to say, I address whether all depri-
vations are the same or should be treated as so. Perhaps some
deprivations are worthy of legal scrutiny and others best left
alone. This idea is simple to grasp, but as Devon Carbado as-
serts, "simple ideas often mask complex social realities."35 Lest
these decisions as to how we conceptualize the body for purposes
of legal remedy be measured by diverse religious criteria or epi-
sodic moral outrage (in other words recent incidences of tissue
banks misappropriating human tissue and bones from funeral
homes), let us consider what the law should be.
Therefore, in Part I, I offer three simple thought experi-
ments to study whether some deprivations amount to a legally
cognizable wrong. Rather than view the harms in terms of a hi-
erarchy of wrongs, I argue for a different approach, one that for
now treats the status of the body equally. I necessarily concede
that not all bodies are situated equally, as the status of the body
follows the social, political, and economic status of the citizen or
individual. That said, this Article puts aside the question as to
whether a particular harm to bodies unequally situated creates
an unequal harm. Part I concludes by examining the pitfalls of
judicial formalism. It argues that our indifference to "naming"
the body and denying it a defined legal status in this biotechno-
33 See, for example, Ryan M.T. Iwasaka, Note, Chakrabarty to Chimeras: The Grow-
ing Need for Evolutionary Biology in Patent Law, 109 Yale L J 1505, 1506 (2000) (dis-
cussing the "tumultuous and confusing decade-long struggle over the patentability of
animals," and the need for modernization in the patent law field to keep apace with ever-
expanding technological discoveries).
34 See Greenberg v Miami Children's Hosp Research Inst, Inc, 264 F Supp 2d 1064 (S
D Fla 2003) (denying relief for families whose donated cell lines and fluids were later
patented by their physician); Cryolife, Inc v Superior Court, 110 Cal App 4th 1145 (Cal Ct
App 2003) (denying strict liability recovery for plaintiff who purchased contaminated
body part from Cryolife tissue bank); Bauer v NFulton Med Ctr, 527 SE2d 240, 244 (Ga
Ct App 1999) (concluding that a widow could not maintain a claim for conversion based
on the unauthorized removal of her husband's eye tissue).
35 Devon Carbado, Race to The Bottom, 49 UCLA L Rev 1283, 1285 (2002).
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logical era renders the law weak and ineffectual. It explores spe-
cific cases and adopts a narrative framework for the Article.
In Part II, I suggest that valuing the body differently de-
pending upon the setting and misfeasor of the harm does not
provide a stable foundation on which the law can rest, nor pre-
dictability for the aggrieved, nor a deterrent to body part pros-
pectors. Furthermore, scholars are mistaken to argue that to as-
sign a value-based or market status to the body for which a rem-
edy can be granted would create a disincentive for producers of
human-based biologics to create medicines or retard biotechnol-
ogy and scientific creativity.
In Part III, I turn to the difficulties of changing the nomen-
clature and status of the body. The technical aspect of such reor-
ganization is easy enough; legislatively, judicially, or both, the
introduction of legislation or adaptation in the common law will
not be difficult-the foundation for this already exists as briefly
discussed in Part III. What I propose, an alternative conception
of the body in light of biotechnology, requires a fundamental re-
evaluation of the body. This invites certain perspectives and dia-
logues that may be deemed offensive to various classes of people.
There are pitfalls to the introduction of valuations in the body;
those insensitive to America's slave past could promote as the
best alternative a valuation system that starkly resembles (at
least in tone) an auction block where bodies are valued based on
immutable factors of race, gender, or physical ability. Individuals
may wish to go to the marketplace with their body parts in far
greater numbers than they do now and for unforeseen purposes.
We would be sensible to give considerable thought to such con-
cerns and possible consequences. Also, it is possible that we
might go too far to accommodate biotechnology rather than re-
thinking the society that we wish to be in light of the rapid ex-
panse of technology. I conclude by arguing that although pitfalls
to redefining the body exist, our failure to be proactive in light of
privatized biotechnology and its drive for body parts will produce
nefarious systems that will result (as will be demonstrated in
Part IV) in unequal treatment, exploitation of the vulnerable,
and lack of recourse for the aggrieved.
Part IV explores what valuations of the body truly mean in a
socioeconomic context. It recommends two specific causes of ac-
tion for the two spheres of biotechnology that most affect the
human body-simply stated, input and output. Thus, Part IV.A
recommends the application of strict liability to cases involving
biotech firms distributing (selling) insalubrious human tissue for
transplantation. Part IV.B proposes that when the state or its
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agent, including scholars funded by federal grants or at state
universities, nonconsensually assume ownership over an indi-
vidual's body (or parts), a "taking" has occurred for which reme-
dies should exist. This article concludes in Part V.
I. PROPERTY, STATE POSSESSION, OR SERVICE?
In Part I, I illuminate three conceptions of the body and
identify the flaws in each model. The first conception, the Moore
model, based on a case ubiquitously read during law school, will
be more familiar to law audiences. The other two conceptions are
slightly more obscure. Most obvious in these thought experi-
ments is that a wrong has occurred. Defining what that wrong is,
in light of contemporary formalistic jurisprudence and legislative
silence, is another matter.
A. The Moore Model: Body Part As Intellectual Property
Model A:
If G (physician) persuades M to have his spleen removed
(under pretense of imminent death), and M complies, but
is unaware that G has pre-established pecuniary and or-
ganizational interests (established business relation-
ships) in exploiting the spleen and cells, and G and his
associates actively exploit the cells, and G withholds this
information from M, including notice of a patent derived
from the use of M's spleen, sperm, and blood, has there
been a violation of M's rights? If so what kind? Can a
claim be made for which relief is available?
Model A(2):
X, clueless, kept raw diamonds in his pocket, but was
convinced by Y (his lawyer) to remove the diamonds to
save his life, and X complied. Y conspired to and did ob-
tain the diamonds after X removed the diamonds from
the pocket. Three years later, the newly polished, cut
diamonds are ready for the market and Y successfully
transfers them to new owners for millions of dollars. Has
there been a violation of X's rights? If so what kind? Can
a claim be made for which relief is available?
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Model A, based on Moore v Regents of the University of Cali-
fornia,36 is perhaps the most recognized body part appropriation
case. On October 8, 1976, Dr. David Golde, an employee of the
University of California at Los Angeles Medical Center, informed
Mr. Moore "that he had reason to fear for his life, and that the
proposed splenectomy operation ... was necessary to slow down
the progress of his disease."37 Moore consented to the operation.
Within days of the meeting with Moore, Dr. Golde and Shirley
Quan, a researcher at UCLA, formed a partnership with the in-
tent of making "arrangements to obtain portions of [Moore's]
spleen following its removal and to take them to a separate re-
search unit."3" Over the next few years, Golde subjected Moore to
additional tests (extracting blood, sperm, bone marrow, and
other fluids), inducing him to commute to Los Angeles from Seat-
tle under the pretense of medical necessity.39 Nearly three years
later, according to the court record, "Golde established a cell line
from Moore's T-lymphocytes."4 ° In 1981, the Regents applied for
a patent on the cell lines and listed Quan and Golde as "inven-
tors,"41 the royalties and profits from which would be shared by
the inventors and Regents. It is estimated that billions of dollars
have been recouped from the exploitation of Moore's spleen and
other tissues.
Without an appreciation for "what" the legal status of
Moore's cells, sperm, and spleen were, the justices were ill
equipped to define what the legal remedy should be. The court,
finding that there was no other judicial or legislative guidance
that would treat Moore's spleen and the cell line as property,
dismissed his conversion claim.42 To suggest, as the court did,
36 793 P2d 479 (Cal 1990).
37 Id at 481 (internal quotation marks omitted).
38 Id (internal quotation marks omitted).
39 Id.
40 Moore, 793 P2d at 481. The particular lymphocyte derived from Moore's spleen is
described as:
[a] type of white blood cell. T-lymphocytes produce lymphokines, or proteins that
regulate the immune system. Some lymphokines have potential therapeutic value.
If the genetic material responsible for producing a particular lymphokine can be
identified, it can sometimes be used to manufacture large quantities of the lym-
phokine through the techniques of recombinant DNA.
Id at 481 n 2.
41 Id at 482.
42 Moore, 793 P2d at 488. Moore's original complaint raised thirteen causes of action.
The court observed, "each defendant demurred to each purported cause of action. The
lower court, however, expressly considered the validity of only the first cause of action,
conversion." Id. The court reasoned that the other causes of action were defective. The
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that his biological materials were sui generis, addresses only
Moore's health condition, but provides little guidance as to the
plaintiff's legal status. The court incorrectly suggests that there
was no possessory interest in Moore's cell line. In fact, Dr. Golde
possessed an interest protected by law. But why didn't Moore?
If "clueless" man, X, can have an interest in the diamonds in
his custody, how can we deduce that one lacks an equal interest
in his spleen, cells, sperm, and other biological materials? The
distinction seems arbitrary; crafting a rule where skin is the bar-
rier to ownership seems absurd. In other words, diamonds exter-
nal to the skin (in one's pocket) is a possession for which there is
a rule of ownership, but that which is within the skin has no
ownership value? Or that which has external value, has no value
if it is trapped within the body? If Moore had swallowed dia-
monds, would the value of the goods have been lost because they
were no longer external?
Consider also that X's recovery is not limited to his aware-
ness or ability to guess the value of the diamonds. Even the
shamelessly ignorant plaintiff is entitled to relief. If the dia-
monds were worth five million dollars, but he guessed their rela-
tive value at five dollars, the law refuses to be punitive towards
him or punish him for his ignorance, by limiting his recovery to
five dollars.' To do so would unjustly enrich Y, his lawyer, and
provide an incentive for lawyers to defraud their clients. As be-
tween the two models above, the California Supreme Court
would have no difficulty divining the remedy for someone coerced
out of his diamonds by his lawyer. Scholars should not be com-
fortable with the fact that the court would be blind to an equally
hostile action, involving a doctor secretly obtaining his patient's
cell line and exploiting it for his financial interests. In Model A,
G, the physician and his collaborators, were likely in the best
position to honestly describe the value of Moore's body parts.
They were aware of the value that could be derived from isolat-
ing particular products from his cell line. They understood the
other claims included: (1) lack of informed consent; (2) breach of fiduciary duty; (3) fraud
and deceit; (4) unjust enrichment; (5) quasi-contract; (6) bad faith breach of implied cove-
nant of good faith and fair dealing; (7) intentional infliction of emotional distress; (8)
negligent misrepresentation; (9) intentional interference with prospective advantageous
economic relationships; (10) slander of title; (11) accounting; and (12) declaratory relief.
Id at 482 n 4.
4 Ctlfds v Haussecker, 974 SW 2d 31, 38 (Tex 1998) ("[P]ermitting the cause of ac-
tion of a 'blamelessly ignorant' plaintiff to accrue before he or she could possibly have
been aware of the injury would be unjust."). See also Michael Green, The Paradox of
Statutes ofLilmtations in Toxic Substances Litigation, 76 Cal L Rev 965 (1988).
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nature of the market's demand for the products they could de-
rive. G and his collaborators also understood their unique mar-
ket advantage; securing a patent on Moore's cell line gave them a
legal monopoly on all its derivatives. Nevertheless, the Moore
court flatly rejected the concept of selfownership in one's body."
B. Presumed Consent: Body Part As State Good
Model B: The Good Samaritan
B dies of sudden infant death syndrome (SIDS). D, a hos-
pital staff member, removes B's corneas pursuant to a
statute intended to increase the supply of corneas in the
state. Parents later learn of the extraction and file a law
suit, claiming the statute is unconstitutional because it
fails to provide notice and an opportunity to object. Is the
statute unconstitutional? Has a constitutionally pro-
tected right been breached?
Model B represents the presumed consent scheme, which
acknowledges that the body has value as a source of transplant-
able goods. However, that value is gifted to the state unless noti-
fication is given to the state that the gift is revoked.45 First en-
acted in Maryland,46 presumed consent laws operate much like
4 Moore, 793 P2d at 488 (holding that the tort of conversion does not apply to his
"biological materials"). However, the holding in Moore does not signify that harm has not
occurred nor that an injury has not been sustained. Rather, the court does indicate that
damages might be difficult to calculate.
45 Uniform Anatomical Gift Act § 4 (National Conference of Commissioners on Uni-
form State Law 1987).
46 See Md Estates and Trusts Code Ann § 4-509.1 (2005), which sets forth the follow-
ing framework for determining when a corneal may be provided for transplant:
(a) Requirements - In any case where a patient is in need of corneal tissue for a
transplant, the Chief Medical Examiner, the deputy chief medical examiner, or an
assistant medical examiner may provide the cornea upon the request of the Medical
Eye Bank of Maryland, Incorporated ... under the following conditions:
(1) The medical examiner has charge of a decedent who may provide a suitable
cornea for the transplant or research;
(2) No autopsy will be required;
(3) No objection by the next of kin is known by the medical examiner;
(4) No religious objection made by the decedent before his death is known by the
medical examiner; and
(5) Removal of the cornea for transplant will not interfere with the subsequent
course of an investigation or autopsy or alter the postmortem facial appearance...
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substituted judgment, whereby one's choice to pursue or not to
pursue a particular course of action with her body is usurped by
the state.47 Pursuant to statutory authority, medical examiners,
coroners, and their designated personnel are authorized to ex-
tract corneas, heart valves, and other tissues from cadavers
without first obtaining consent from the "donor" if the donor has
not declined a donation.' The illusory opt-out provision veils the
fact that such laws are more like conscription measures and less
like an option or choice. Where, after all, is one to opt out? How
do the dead opt out? How can the uninformed relative opt out?
Indeed, studies demonstrate that most people, even local legisla-
tors such as aldermen and city council members, are relatively
ignorant about presumed consent (in their own states) and pos-
sess a limited understanding of what the term signifies or what
the law authorizes.49
Cornea extraction may be perceived as less invasive than
spleen removal; it certainly is less disfiguring, and thus less no-
ticeable. Cornea extraction does not leave signs easily noticeable
(c) Liability of Medical Examiner, Medical Eye Bank of Maryland etc.-The Chief
Medical Examiner, the deputy chief medical examiner, an assistant medical exam-
iner, and the Medical Eye Bank of Maryland, Incorporated ... are not liable for civil
action if the next of kin subsequently contends that authorization of that kin was
required.
Id.
47 Uniform Anatomical Gift Act § 4 (stating that "[t]he [coroner] [medical examiner]
may release and permit the removal of a part from a body within that official's custody").
48 Ariz Rev Stat Ann §§ 36-851, 36-852 (West 1989); Ark Code Ann. § 12-12-325 (Mi-
chie 2005); Cal Govt Code § 27491.46-.47 (West 2006); Colo Rev Stat § 30-10-621 (2005);
Conn Gen Stat Ann § 19a-281 (West 2005); Del Code Ann § 29-4712 (2004); Fla Stat Ann
§ 765.5185 (West 2006); Ga Code Ann § 31-23-6 (Lexis 1985); Haw Rev Stat Ann § 327-4
(Michie 2004); Idaho Code § 39-3405 (2005); Ill Ann Stat § ch 110 1/2, § 351-354 (Smith-
Hurd 1983); Ky Rev Stat Ann § 311.187 (Michie 2001); La Rev Stat Ann § 17:2354,
33:1565 (West 2005); Md Est and Trusts Code Ann § 4-509.1 (2005); Mass Ann Laws ch
113, § 14 (Law Co-op Supp 1989); Mich Comp Laws Ann § 333.10202 (West 2005); Miss
Code Ann § 41-61-71 (1989); Mo Ann Stat § 58.770 (Vernon 2006); Mont Code Ann § 72-
17-215 (2005); N C Gen Stat § 130A-391 (2003); N D Cent Code § 23-06.2-04 (Supp 1989);
Ohio Rev Code Ann § 2108.60 (Baldwin 2005); Okla Stat Ann § 63-944.1 (West 2006); R I
Gen Laws § 23- 18.6-4 (2001); Tenn Code Ann § 68-30-204 (1989); Tex Health and Safety
Code Ann § 693.012 (Vernon 2005); Utah Code Ann § 26-4-23 (2005); Wash Rev Code Ann
§ 68.50.280 (2006); 2005 Wis Laws § 157.06; W Va Code § 16-19-4 (2005).
49 Ralph Frammolino, Harvest of Corneas at Morgue Questioned, LA Times (Nov 2,
1997) (investigating over 570 cases of nonconsensual cornea harvesting during a 12
month period, and explaining that families "were shocked that they had not been asked
or told"). See also, Michele Goodwin, Organ Transplant Survey Analysis (Feb 16, 2000)
(unpublished, on file with the author). This survey was administered in Lexington, Ken-
tucky, with the assistance of Janet Givens, special assistant to former Mayor Pam Miller.
Participants consisted of administrators in the Mayor's Office and members of the City
Council of Lexington, Kentucky. Only one of fifteen government officials surveyed (or 6.6
percent) in this group was aware of the term "presumed consent," although Kentucky had
authorized legislative consent over ten years prior to the survey.
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to lay people; there are no bruises on the face and no scratches
on the eye lids.5" Thus, if the deceased is prepared for burial, par-
ticularly with her eyes closed, her family would be completely
unaware of the medical intrusion. 1 For this reason, critics of
presumed consent legislation regard these laws as surreptitious
and unethical, while proponents argue that statutory consent
measures are creative efforts to procure corneas. 2 That indi-
viduals can be laid to rest with the appearance of "wholeness" is
persuasive if appearances are the only impediment to broader
support of presumed consent measures. Proponents also argue
that compulsory donations require so little and that families
hardly notice. 3
Presumed consent statutes are compulsory measures that
obligate individuals to donate. The legislation authorizing this
type of body part conscription operates pursuant to mandatory
autopsy statutes.' Thus, the only bodies to which presumed con-
sent applies are victims of homicide or catastrophic deaths re-
quiring a medical investigation. Disproportionately in some
states, blacks and Latinos are the overwhelming majority of the
presumed consent donors.55 In California, according to a 1997
50 See, for example, Frammolino, Harvest of Corneas at Morgue Questioned, LA
Times Al (cited in note 49) (noting that the lack of noticeable physical differences is how
coroners have managed to remove corneas without the knowledge of relatives); S. Gregory
Boyd, Comment, Considering a Market in Human Organs, 4 NC J L & Tech 417, 441
(2003) (discussing a Florida court's characterization of corneal removal as a small intru-
sion).
51 See, for example, Frammolino, Harvest of Corneas, LA Times at Al (cited in note
49); Boyd, 4 NC J L & Tech at 441 (cited in note 50).
52 Marie-Andree Jacob, On Silencing and Slicing. Presumed Consent to Post-Mortem
Organ 'Donation" in Diversified Societies, 11 Tul J Intl & Comp L 239, 254-55 (2003)
(describing the criticism that presumed consent is unethical); Maryellen Liddy, The 'New
Body Snatchers". Analyzing the Effect of Presumed Consent Organ Donation Laws on
Privacy, Autonomy, and Liberty, 28 Fordham Urban L J 815, 819 (2001) (describing that
many supporters believe presumed consent will increase the supply of organs available
for transplant).
5 Linda C. Fentiman, Organ Donation as National Service: A Proposed Federal Or-
gan Donation Law, 27 Suffolk U L Rev 1593 (1993); Boyd, 4 NC J L & Tech at 441 (cited
in note 50); Theodore Silver, The Case For A Post-Mortem Organ Draft and A Proposed
Model Organ Draft Act, 68 BU L Rev 681 (1988).
5 See, for example, Fred H. Cate, Symposium: Organ Donation, Human Organ
Transplantation: The Role of Law, 20 J Corp L 69, 84 (1995) (noting that presumed con-
sent "laws generally provide that a coroner or medical examiner may remove the corneas
from a cadaver in the course of a legally-required autopsy").
55 See Gabriel Escobar, Deaths Pose Continuing D.C. Mystery; City Carries Hun-
dreds of Undetermined Cases, Muddying Vital Statistics, Washington Post Al (Dec 22,
1997) (commenting on the rise in urban violence in the 1980s and remarking that many of
the deaths of black urban Americans from that era remain unsolved); Glen Loury, The
Impossible Dilemma, The New Republic 21 (Jan 1, 1996) (noting that the murder rate
among black youths (under age 20), which was already three times that of white youths
THE UNIVERSITY OF CHICAGO LEGAL FORUM
study, over eighty percent of presumed consent donors were
black and Latino.56 In effect, the state presumes that a potential
donor would in fact have wanted to donate were she still alive
and able to make the choice. As indicated in prior scholarship,
"legislatures are not shielding state regulations that authorize
presumed consent from the public."57 On the other hand, neither
tissue banks, which process and sell the tissues at considerable
profit, nor state governments advertise the existence of such
laws. It is not surprising, as discussed later in the Article, that
tissue banks generate considerable revenue from processing,
storing, and selling cadaver tissues. The tissue banking industry,
which derives its "stocks" of tissues through mostly clandestine
means, is estimated to be more than a billion dollar industry.
The compulsory aspect of the regulations makes these dona-
tions problematic. Forced use of nonconsenting individuals' tis-
sues is justifiable only if the donation is viewed as a form of civic
duty, or if our bodies are property of the state. Donation as a
civic duty is a laudable concept, though not supported by social
custom or an American legal tradition. Our common law tradi-
tion abjures the duty to rescue doctrine, and more pointedly
warns, "rescue at your own risk." That our bodies belong in ser-
vice to the state cannot be justified by the ways in which we or-
ganize labor, medicine, or our system of justice. Marx's concept of
a communitarian society, operating for the common good of man
and woman, no matter how laudable, is not a philosophy that
constitutional framers or the subsequent generations of elector-
ate have adopted. This notion of compelled altruism belies the
reality that only twenty percent of Americans carry donor
cards-a more realistic reflection of their affirmative intent to
donate.
in 1986, doubled in the five years between 1986 and 1991, while the white rate remained
unchanged). See also Darryl Fears, Urban Spotlight: Is Atlanta the Next Detroit At-
lanta J & Const D1 (Dec 18, 1994) (pointing out that in the early 1980s, the homicide rate
soared). Fears reports that between 1983 and 1987, more than 700 people were slain each
year. On No Crime Day in Detroit-a 1986 event sponsored by basketball star Isaiah
Thomas to prove his city was still safe-a police officer was shot dead. Id.
56 Frammolino, Harvest of Corneas, LA Times at Al (cited in note 49). See also The
Late Edition: Crime in the US. is Discussed (CNN television broadcast) (Transcript # 4-
2) (Oct 24, 1993); Eric Lichtblau, Reporter's Notebook: Going beyond Line Scores of Gang
Carnage, LA Times B3 (Nov 25, 1990) (noting that during a one month time span there
were over 300 gang-related killings in Los Angeles County); Larry King Live: Spjng on
Neighbors-The New Drug- War Strategy (CNN television broadcast) (Transcript # 108-2)
(Aug 15, 1990).
67 Michele Goodwin, Black Markets: The Supply and Demand of Body Parts 17
(Cambridge University Press 2006).
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Model B raises questions about duty, notice, appeal, and due
process. In Georgia Lions Eye Bank, Inc v Lavant, s parents of an
infant (dead as a result of SIDS) filed suit against the eye bank
that was authorized by the state medical examiner to remove
their son's corneas. The parents were not consulted and therefore
had not authorized the removal. Essentially, they were denied
the opportunity to object to the extraction.59 The trial court held
in favor of the parents, opining that the imposed consent statute
violated due process in that it deprives a person of a property
right in the corpse of her next of kin, and fails to provide notice
and an opportunity to object.60 Their complaint relied on a com-
mon law duty to properly bury and dispose of the deceased im-
posed by ecclesiastical courts on the next of kin of deceased per-
sons.6 Over time, this duty became interpreted and litigated as a
"right" to dispose in any "appropriate" and "decent" manner af-
forded by the relatives.62 Despite its own common law tradition
upholding quasi property right interests in the dead for the next
of kin, the Georgia Supreme Court reversed, ruling that parents
have no interest in the body of their dead children.
The ruling in Georgia Lions belied the status of dead bodies
within the common law on the point of quasi property right in-
terests. Previously, Georgia courts, as have other US courts,
fashioned a "quasi property" right out of the duty to bury. Quasi
property right interests in the dead were affirmed by a Georgia
court in the 1937 Pollard v Phelps" case, which established that
"the courts of civilized and Christian countries regard respect for
the dead as not only a virtue but a duty, and hold that, in the
absence of testamentary disposition, a quasi property right be-
longs to the husband or wife, and, if neither, to the next of kin."65
Thus, if quasi property rights represent a substantive liberty,
then it would seem that a violation of those interests occurs
58 335 SE2d 127 (Ga 1985).
59 Id at 128.
60 Id.
61 Id. See also Rivers v Greenwood Cemetery, 22 SE2d 134, 135 (Ga 1942) (holding
"that a dead body is quasi property over which the relatives of the deceased have rights
which the courts will protect").
62 Kathryn E. Peterson, Note, My Father's Eyes and My Mother's Heart: The Due
Process Rights of the Next of Kin in Organ Donation, 40 Valp U L Rev 169, 186 (2005)
(arguing that the "next of kin have a right to bury the body of a decedent in an appropri-
ate manner").
63 Rivers, 22 SE2d at 134.
64 193 SE 102 (Ga Ct App 1937).
6 Id at 106.
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when a state encroaches upon those spindles of "rights" without
due process even in a utilitarian system designed to benefit a
public purpose.
"Quasi property" rights diminish in their perceived value
unless such interests can be protected from arbitrary state ac-
tion. The Georgia Lions court's assertion that statutory enact-
ments naturally trump common law rules is correct only in in-
stances when the statute itself does not violate constitutional
protections.66 Brown v Board of Education7, which provided that
all provisions of state laws and regulation must yield to the prin-
ciple that racial discrimination is unconstitutional, as well as
Skinner v Oklahoma,6" which overturned state mandated sterili-
zation of persons considered "habitual criminals,"69 demonstrate
a well-established principle that legislation is subject to judicial
scrutiny and more importantly constitutional protections. These
cases persuasively remind us that regulations crafted from legis-
lative authority are neither absolute nor immune from constitu-
tional scrutiny. 0
Thus, in the transplantation context, whether presumed
consent laws can pass constitutional muster deserves serious
judicial scrutiny. Because presumed consent procurement is trig-
gered by homicide deaths in most states rather than all deaths,
the line of proscription becomes arbitrary as the statute requires
66 Newman v SatiyavagIswaran, 287 F.3d 786,797 (9th Cir 2002) (explaining that
"although the underlying substantive interest is created by 'an independent source such
as state law,' federal constitutional law determines whether that interest rises to the
level of a 'legitimate claim or entitlement' protected by the Due Process Clause") (quoting
Memphis Light, Gas and Water Div v Crat, 436 US 1, 9 (1978)).
67 347 US 483 (1954).
68 316 US 535 (1942).
69 Id at 536. Oklahoma's Habitual Criminal Sterilization Act, Okla Stat Ann §§ 57
171-95 (1935) defined a "habitual criminal" as:
a person who, having been convicted two or more times for crimes 'amounting to
felonies involving moral turpitude' either in an Oklahoma court or in a court of any
other State, is thereafter convicted of such a felony in Oklahoma and is sentenced to
a term of imprisonment in an Oklahoma penal institution.
Skinner, 316 US at 537.
The statute required that all men and women who were "habitual criminals" sub-
mit to sterilization. Men were to receive vasectomies and women salpingectomies. The
legislature was convinced that such operations could take place (for the health and safety
of the community) without being a "detriment to his or her general health." The legisla-
ture, however, took pains to make clear that "offenses arising out of the violation of the
prohibitory laws, revenue acts, embezzlement, or political offenses, shall not come or be
considered within the terms of this Act." Id at 536-37.
70 See id at 535 (overturning Oklahoma's Habitual Criminal Sterilization Act that
provided for the sexual sterilization of individuals convicted of three or more felonies of
moral turpitude).
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only those whose deaths resulted from murder or catastrophic
injury to surrender body parts. And although limited in scope,
this rule is not narrowly tailored to achieve its stated goal.
Rather, a narrow tailoring here might advisedly involve mecha-
nisms for consent and refusal to donate despite the laudability of
body part donation.
Crafting a donor pool that draws primarily from homicide
victims can exacerbate class and race distinctions. 71  But most
importantly, the rule burdens only one classification of the de-
ceased.72 Effectively the law distinguishes the right to bury and
even donate by mode of death. Yet constitutional rights are nei-
ther so arbitrarily defined nor abridged.
If legislators truly believe that Americans support presumed
consent policies, why not require babies to surrender one kidney
at birth? Only one kidney is needed for a full and healthy life. It
is conceivable that the burdens and risks associated with this
type of procurement process could be justified by the benefits
inured to others. Harvests could be done at the time of vaccina-
tion. Doctors could monitor the healing process. Parents would
be more informed participants. Relatives, in town for the birth,
could provide support and comfort the parents and child. For the
baby, the scars would heal seamlessly and more importantly, a
life would be saved or extended, at least, for ten to fifteen years.
Every child in the United States would be part of a plan to "gift"
life to another. This would surely cure the organ shortage. But
alas, Americans are not so generous; nor as a nation have we
embraced this type of horrific altruism.
To be sure, there is a lesser expectation of personal privacy
for public health initiatives that guard against diseases, such as
compelled vaccinations,73 than for policies requiring individuals
to surrender their bodies so that vital parts may be plucked out
to benefit the common good. The line is not fine. To the contrary,
71 Frammolino, Harvest of Corneas, LA Times at Al (cited in note 49) (noting the
overwhelming primary pool of presumed consent donors in Los Angeles were black and
Latino homicide victims). Michele Goodwin, Deconstructing Legislative Consent Law:
Organ Taking, Racial Profiling, & Distributive Justice, 6 Va J L & Tech 2 (2001).
72 If the objective of saving lives through transplantation were a compelling enough
function for the state, which justified ignoring privacy, religious freedom, due process,
and eliminating a principle right to bury, why limit the compelled donor pool to homicide
victims or those who die by catastrophic circumstances? Doing so places the body part
supply burden on a narrow population already aggrieved by the unanticipated loss.
73 Jacobson v Massachusetts, 197 US 11 (1905) (upholding the constitutionality of a
compulsory smallpox vaccination on the ground that it had a real and substantial relation
to public health and safety); McCormick v Stalder, 105 F3d 1059 (5th Cir 1997)(finding
constitutional a policy to forcibly vaccinate prisoners against tuberculosis).
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vaccinations reasonably serve an interest that most Americans
are inclined to support. However, even with this lesser expecta-
tion of privacy in vaccination cases or pregnancy testing for AIDS
and HIV, there is powerful and persuasive dissent in the public
sphere, which indicates that Americans are deeply concerned
about their personal privacy, religious freedom, quality of life,
autonomy, and the desire to be "free" from government interfer-
ence or intrusion on their bodies.74 That the statutory provisions
on which presumed consent laws are implemented rely upon sur-
reptitious planning and clandestine operations in coroners' of-
fices or during autopsies with medical examiners-usually with-
out the consent of relatives-indicates their statutory weakness.
C. Blood Shield Law Model: Body Part As a Service
Model C: Buyer Beware
P, a college student, receives a knee implant (a tendon)
from tissues bought from TB. The implanted tissue is
later found to be contaminated with bacteria typically
found in the human bowel. P becomes gravely ill and dies
four days later. His estate, learning that TB was aware
of the contamination prior to selling the tissues, sues un-
der a theory of product liability. Does the estate have a
claim for which relief can be granted?
Few courts have ruled on the issue as to the status of a
commercialized body part or whether the purchasers of such
parts have recourse when the body parts are defective or con-
taminated. Those that have, as in Cryolife, Inc v Superior Cour 5
and Condos v Musculoskeletal Transplant Foundation,76 ruled
that bone tissues sold for transplantation were not actually
products or goods (although arguably property of their sellers),
but rather services.7 7 Such rulings leave duped purchasers with-
74 See Hill v Evans, 1993 US Dist LEXIS 19878, *17 (M D Ala 1993) (finding uncon-
stitutional an Alabama law authorizing HIV testing of "high risk" patients); Dan Olm-
sted, The Age ofAutism: Christian's Mom Speaks, UPI (Apr 12, 2006) (highlighting an
influential parent's campaign to propose and implement alternatives to mandatory vacci-
nations); Katherine Seligman, Vaccination Backlash; There's A Small But Stubborn Fac-
tion Of Parents Who Don't Vaccinate Their Children. Are There Risks, The San Fran-
cisco Chronicle 8, (May 25, 2003); Michael Lasalandra, BU Expert Faults CDC for Vac-
cine Backlash, The Boston Herald A4 (Feb 8, 2003); Joan Lowy, Vaccination Backlash
Worries Doctors, Pittsburgh Post-Gazette A3, (May 9, 1999).
75 Cryolife, 110 Cal App 4th 1145 (Cal Ct App 2003).
76 208 F Supp 2d 1226 (D Utah 2002).
77 Cryol'fe, 110 Cal App 4th at 1159; Condos, 208 F Supp 2d at 1230.
336 [2006:
317] FORMALISMAND THE LEGAL STATUS OFBODYPARTS 337
out a cause of action and tissue banks free from liability. The
rulings indicate that the status of the body can change from one
handler to the next. Both cases expose a problematic public pol-
icy. Now, to be sure, the courts in these cases recognized the
ownership interest or property interests in body parts. The rele-
vant question remains: who is the possessor or owner of body
parts in the stream of commerce? One way to interpret these
transactions that seems fairly consistent with the holdings is
that the patient owned the tendon he purchased. The tissue
banks "owned" the tissues prior to selling them. However, it ap-
pears from the logic of Cryolife that as soon as the good leaves
the warehouse of the tissue bank, the body part becomes a "ser-
vice.""8 Thus, the cases illuminate inconsistent treatment vis-A-
vis the status of body parts. For example, commercial exploiters
of human tissues buy, process, and sell the biological materials to
patients via doctors and hospitals. Yet, the Condos and Cryolife
rulings conclude that tissue banks should not be held liable for
placing contaminated tissues into the stream of commerce even if
their products cause the deaths or illnesses of consumers.
The contaminated tissue cases on which Model C is based
represent a third class of litigation explored in Part I that in-
volve the difficulties of naming body parts and their legal status.
The model is based on the tragedy of Brian Lykins. His life was
cut short after a routine knee operation. According to one of the
lawyers involved in the litigation that I interviewed for this Arti-
cle, Brian needed only the equivalent of a pin to be placed into
his knee. Brian was healthy and an outgoing twenty-three year
old engineering student.79 He was a self-taught musician and
very close to his family. 0 The operation he required was a rou-
tine, out-patient knee surgery."' What Brian received was more
than he bargained for; Cryolife, the company that sold the ten-
don to transplant into Brian's knee, processed it from a cadaver,
78 Cryolife, 110 Cal App 4th at 1145.
79 See M.A.J. McKenna, Tissue Transplant Firm Linked to 14 Infections, Atlanta J &
Const Al (Mar 15, 2002) (discussing the death of Bryan Lykins, a student in Minnesota,
who died of bacterial infection as the result of his knee surgery).
80 Cryolife Litigation, available at <http://www.cryolifelitigation.com/bio.asp> (last
visited Apr 13, 2006).
81 See Robert Pear, FDA Delays Regulation of Tissue Transplants, NY Times A18
(May 14, 2003) (noting that Brian Lykins died after undergoing a "routine knee surgery").
Amanda Gardner, US. Strengthens Rules Governing Tissue, Organ Transplants, Health
Day (Nov 19, 2004) available at <http'/thedoctorslounge.e-healthsource.
com/index.php?p=newsl&&id=522463> (last visited May 6, 2006) (describing Brian
Lykins' surgery as "routine"). See also <http'/fhealthinfo.nmh.org/healthnews/ health-
day/041119HD522463.htm> (last visited April 24, 2006).
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which remained unrefrigerated for nineteen hours.82 The cadaver
from which the allograft was acquired had been rejected by other
tissue processing companies.83
Despite Cryolife's tests on the cadaver, which revealed infec-
tion, the company sold the tendon at a tremendous mark-up to
the hospital where the operation took place.' On November 7,
2001, Brian's new tendon was implanted.5 Within hours, his con-
dition rapidly deteriorated.86 By the evening of the operation he
was extremely ill.8 7 In four days, he was dead.88 He died Novem-
ber 9, 2001 as a result of an allograft which had been contami-
nated with bacteria from the bowel of the cadaver from which
parts were processed and sold by Cryolife.89
Several problems attend human tissue transplantation and
the reconstitution of body parts beyond the question of owner-
ship. First, are warranties appropriate for reconstituted, proc-
essed, or restructured body parts? Second, should recourse be
granted for purchasers who unwittingly buy insalubrious tis-
sues? Third, how do we frame remedies for injured plaintiffs-
through tort or contracts law? Some of these problems are illu-
minated in disturbing narratives, including those of Bonny Gon-
yers, Ken Alescu, Sydney Steinberg (a five year-old who died
from a heart valve infection possibly linked to CryoLife, the sup-
plier of the body part that she received), and similar cases.90 In
82 Gardner, US. Strengthens Rules Governing Tissue, Health Day (Nov 19, 2004)
(cited in note 81).
83 See Sandra Blakeslee, Lack of Oversight in Tissue Donation Raising Concerns, NY
Times 11 (Jan 20, 2002) (noting that "[i]n many parts of the country, tissue banks that
have contracts with for-profit companies will accept donors other tissue banks have re-
jected as unsafe for use").
84 But see Transplant Medicine, Immunotherapy Weekly 13 (Sept 11, 2002) (noting
that Cryolife allegedly failed to test for the germ that caused the deadly infection).
85 See Tissue Banks: The Dangers of Tainted Tissue and the Need for Federal Regu-
lation: Hearing Before the US Senate Committee on Homeland Security and Governmen-
tal Affairs, Senate Committee on Governmental Affairs, 108th Cong, 1st session, *7
(2003) (testimony of the parents of Bryan Lykins) available at <http'//hsgac.senate.gov
/_files/shrgl08ll0tissuebanksreg.pf>) (last visited Feb 16, 2006) (hereinafter "Lykins
Hearings").
86 Id at *8.
87 Id.
88 See David McNaughton, CryoLife Tries to Bounce Back; Tissue Recall by FDA
Spawns Losses, Atlanta J & Const D1 (Aug 28, 2003) (noting that Brian Lykins died from
"[c]lostridium sordelli, a bacteria that spreads from the intestine to the rest of the body
after death").
89 Id.
90 See Sandra Blakeslee, Recall is Ordered at Large Supplier of Transplant Tissue,
NY Times Al (Aug 15, 2002) (discussing the FDA's order for Cryolife to recall all soft
tissues it had sold).
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each instance, plaintiffs suffered injuries connected to the im-
plantation of infected human tissue. Severe injuries and even
deaths occurred not as a result of the surgical malfeasance, but
due to diseased tissues spreading deadly bacteria within the
transplant hosts' bodies. Thus, the issues in dispute with relation
to the cases were less about the cause of the injuries, but rather
whether remedies exist for these injuries.
The question as to remedies becomes all the more relevant
given the significant demand for body parts and the growth of
the tissue transplantation and genetic bioprospecting indus-
tries.9 ' This technology is useful, but imprecision and mistakes
are likely to occur at many stages. And it seems likely that these
problems will only increase. According to one reporter, tissue
transplants, "fueled largely by demand for tissue for spine sur-
gery ... has become a billion-dollar industry."92 In 2004, "there
were about a million tissue transplants in the United States."93
That figure represents nearly a three-fold increase in one dec-
ade.94 To the extent that treatments are now available for worn-
out knees and joints and defective or blocked heart valves, doc-
tors will continue to recommend these types of elective treat-
ments for their patients. Their failure to do so might be action-
able itself; failure to enhance, even by chance, a patient's health
outcome can result in civil liability in a growing number of juris-
dictions.95
Nevertheless, problems are unresolved, even with the Center
for Disease Control's ("CDC") investigations revealing the nu-
merous problems at tissue bank laboratories, and as will be dis-
cussed, the very direct links between the deaths and illnesses of
consumers and cadaver sources used by the companies that proc-
essed and sold the body parts that they purchased. Recent court
decisions unwisely place the burden on patients and doctors to
guard against implanting contaminated body parts.96 Yet, how
91 Rebecca Skloot, Taking the Least of You, NY Times Mag 38 (Apr 16, 2006).
92 Renie Schapiro, Banking on the Gift of Tissue, Milwaukee J Sentinel G1 (May 2,
2005).
93 Id.
94 Id.
95 Margaret T. Mangan, The Loss of Chance Doctrine: A Small Price to Pay for Hu-
man Life, 42 SD L Rev 279, 291 (1997) ("Most courts which have had an opportunity to
decide upon the loss of chance doctrine recognize a cause of action for loss of chance in
medical malpractice actions."). See also Delaney v Cade, 26 F3d 991(10th Cir 1994) (con-
cluding that Kansas recognizes loss of chance); LaRose v Washington Univ, 154 SW3d
365, 370 (Mo Ct App 2004) (awarding damages against physician whose failure to diag-
nose cancer in patient reduced her chance of survival).
96 Cryolife, 110 Cal App 4th at 1145; Condos, 208 F Supp 2d at 1226; Lenahan v Univ
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are patients, often the least informed, to police this process?97
Patients, and even their doctors, are simply uninformed and it
would seem unreasonable to expect them to know health and
lifestyle information about the cadavers from whom the body
parts are harvested.98
Recent controversy involving the pillaging of body parts from
funeral home cadavers in New York and New Jersey further il-
luminates this point. In February 2006, the Brooklyn District
Attorney Charles Hynes charged four grave pillagers with "medi-
cal terrorism."99 Hynes claimed the body-robbing scandal was
"unique in its utter disregard for human decency.""' It was the
latest horrific episode in the ongoing tissue transplant industry
saga. The indictment alleges that a New Jersey dentist, Michael
Mastromarino, and codefendants robbed over a thousand bodies
of bones, ligaments, heart valves, organs, and other valuable tis-
sues.' The defendants stuffed the bodies with plastic tubing to
deceive relatives. 0 2 Detectives and investigators unmasked their
furtive scheme, but only after thousands of body parts, some
from diseased corpses, were sold for transplantation to hospitals,
doctors, and patients throughout the United States' 3 and inter-
nationally.1°" Tissue, similar to blood transfusions, can transmit
hepatitis, HIV, mad cow disease, bacteria, and various other
communicable diseases to the unsuspecting transplant recipient.
That patients and their doctors are at a practical disadvan-
tage seems clear. 0 Both parties lack information about the ca-
of Chicago, 808 NE2d 1078, 1087 (Ill App 2004) ("Plaintiffs failed to allege facts sufficient
to show that the defendants knowingly and voluntarily participated in a common scheme
to commit any tortious acts in relation thereto."); Johnson v Superior Court, 101 Cal App
4th 869, 886-89 (2002) (limiting the recovery of parents seeking damages because sperm
bank failed to disclose that purchased sperm came from a donor with a history of kidney
disease, which the daughter now has).
97 Law Firms Fle Suit on Behalf of Transplant Patient Who Allegedly Received file-
gaily Harvested Body Parts; Suit Alleges That Untested Bones in Transplant Led to Posi-
tive Hepatitis Test Results, Bus Wire (Mar 23, 2006) available at
<http:Hhome.businesswire.com/portal/site/google/index.jsp?ndmViewId=newsoview&news
Id=20060323005497&newsLang=en> (last visited May 6, 2006).
98 Id.
99 Tonya Maxwell, 4 Charged With Stealing Bones Implanted Locally, Chi Trib
C3 (Feb 24, 2006).
1oo Anthony M. Destefano, The Body Snatchers: Funeral Home-Based Ring Charged,
Newsday A03 (Feb 24, 2006).
1O1 Id.
102 Id.
103 Id.
104 Daryl Passmore, The Body Business, The Sunday Mail 57 (Australia) (July 1,
2006).
105 Spring of 2006, I was interviewed along with two surgeons for a nightly news pro-
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davers' lifestyles, sexual habits, prior illnesses, and whether the
"donors" smoked, were alcoholic, or used drugs. Surgeons, though
skilled, are not microbiologists and lack the expertise, resources,
and luxury (at the time of surgery) to perform sophisticated mi-
crobial analyses on heart valves and tendons. Equally, anesthe-
tized patients are unprepared to test or know that they should
test the products purchased from tissue banks before or during
surgery and implantation. Thus, placing the onus on patients
and their physicians to be the gatekeepers to these industries is
simply unreasonable for purposes of public policy, particularly
given that tissue banks are in the best position to test their own
products before placing them into the streams of commerce. Fur-
ther, that many tissue banks, including Cryolife, the source of
much litigation, °6 are for-profit, truly distinguishes the industry
from not-for-profit blood processors such as the Red Cross." 7
It is here that the story of tissue giant, Cryolife, its litigation
history, clients' narratives, and setbacks are instructive for pub-
lic policy analysis. Despite lawsuit settlements against Cryolife,
the Court of Appeals of California determined in 2003 that Cryo-
life and arguably other tissue banks are immune from liability
for the body parts they place into the stream of commerce.' Ac-
gram in Chicago, Illinois. The doctors had transplanted possibly insalubrious tissues in
patients here in Chicago. The tissues were processed from a tissue bank now closed and
under investigation by the attorney general's office in New Jersey. The discovery that the
tissue bank purloined body parts from a funeral home was disclosed only after the sur-
geons implanted tissues from cadavers that may have carried diseases or from individu-
als who died from cancer. Patients across the United States are now being tested for
hepatitis and other communicable diseases. Several lawsuits have been filed. See Chicago
Tonight, Feb 2, 2006. See <http/www.wttw.com/main.tafp=1,4,4,1&Date=01%2F29%2
F2006>.
106 See for example, In re Cryolife, Inc Sec Litig, 2003 US Dist LEXIS 26170, *36-
38 (N D Ga 2003) (finding stock purchasers sufficiently alleged securities fraud by alleg-
ing that, after a transplant recipient died from contaminated tissue provided by a corpo-
ration, the corporation misrepresented its quality standards and compliance with regula-
tions); Cryolife, Inc v Superior Court, 110 Cal App 4th 1145 (Cal Ct App 2003) (holding
that tissue bank provided a service and not a product by collecting, storing, and selling
body parts); Talton v Arnall Golden Gregory, LLP, 622 SE2d 589, 592-93 (Ct App Ga
2005) (concluding that injured patient failed to show that lawyers for Cryolife ever in-
tended for their advice regarding tissue warning labels to be disclosed to or relied on by
third parties, or that, when lawyers consulted with client corporation, they were "actually
aware" that patients would rely on such confidential advice).
107 The Food and Drug Administration ("FDA") does not require companies to be a
registered member of a certified tissue bank association, such as the Tissue Bank Asso-
ciation of America ("TBAA"). Rather, each company selects its own method for testing
tissues, determining whether it will test and treat tissues at all, and whether it will in-
form patients and physicians about the results of those tests. FDA, Keeping Human Tis-
sue Trmsplants Safe, FDA Consumer Mag Vol 39:3 (May-June 2005), available at
<http'//www.fda.gov/fdac/features/2005/305_tissue.html> (last visited Apr 13, 2006).
108 See Cryolife, 110 Cal App 4th at 1155 (concluding that the California Health and
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cording to the Court of Appeals of California, Cryolife's immunity
from placing insalubrious tissues in the marketplace arises from
the fact that buying, collecting, processing, storing, and selling
body parts are collectively and essentially a "service" and that
the parts sold are not "goods."'0 9
The Cryolife"° holding invites scrutiny as to how body parts
should be classified and what their legal status ought to be. In
facts similar to Model C, Alan Minvielle sued the tissue bank
after the allograft he received was found to be contaminated by
deadly bacteria."' The court's conclusion that body parts are a
service rather than the performance of a service precluded his
recovery and is a striking feature of the case." ' It is a conclusion
that is hard to support; arguably few people would consider his
or her knee, heart, hip, or spine a service. Likewise, of course,
tissue banks leery of litigation are equally reluctant to treat
knees as goods, which will expose them to liability when con-
taminated cadaver tissues are placed into the stream of com-
merce. This tension and incoherence in the law exposes the need
for a common lexicon and understanding of the legal and social
status of cadaver body parts and tissues. Arguably, in the chang-
ing function and use of body parts, our common understanding of
the parts' post-harvesting classification should also evolve. In
other words, what Cryolife processes describes its service, what
it produces through that processing is a good or product for
which it receives value.
The relevance of this point proved significant to the court's
analysis of the case and whether the plaintiff could pursue a
strict liability claim for punitive damages against the tissue
bank. Ultimately, the Court of Appeals of California was not per-
suaded by the plaintiff's charge that Cryolife did not fit within
the legislative exemption provided for blood banks." 3 California
and a majority of states enacted blood shield immunity statutes
during the 1950s and throughout the subsequent two decades to
Safety Code "provides statutory immunity from strict liability to tissue banks subject to
regulation").
109 Id ("By expressly deeming such activities to constitute a service, the Legislature
must have intended a tissue bank to be immune from strict liability, just like a phar-
macy.").
110 Id.
... Id at 1148.
112 Cryolife, 110 Cal App 4th at 1154-55.
113 Id.
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shield organizations that collected and processed blood from
strict liability claims.114
Cryolife contended that the Health and Safety Code provi-
sions of California, which define the status of tissue banks,
barred plaintiffs from strict liability claims against tissue
banks.'15 The statute, however, does not explicitly provide such
an exemption or immunity to tissue banks. Rather, Section 1606,
the codification of the blood shield law, provides in pertinent
part:
[t]he procurement, processing, distribution, or use of
whole blood, plasma, blood products, and blood deriva-
tives for the purpose of injecting or transfusing the same,
or any of them, into the human body shall be construed to
be, and is declared to be, for all purposes whatsoever, the
rendition of a service by each and every person, firm, or
corporation participating therein. 16
The public policy rationale for blood shield laws was to pro-
mote an adequate blood supply, particularly as most surgeries
requiring blood are not elective, but rather a matter of life and
death. Thus, the policy militates against liability in the absence
of a negligent or intentional tort. Yet, whether the same ration-
ale should hold true for tissue banks is a different matter.
Ultimately, the court agreed with Cryolife's nuanced defini-
tion of its business. The tissue bank claimed that its business
status, although for profit, is similar to that of blood banks-
which traditionally have been not-for-profit-within the defini-
tion of the blood shield immunity law."7 Both sections of the law
(1606 and 1635.2) describe the banks as providing services, how-
ever, only the blood shield statute provides an immunity provi-
sion-and only for blood banks."' Despite the "difference in lan-
guage of section 1606 and section 1635.2, " ' 1 the court held that
the legislature must have intended to shield tissue banks from
strict liability claims.
The court's analysis leaves much to be pondered considering
its leap is not supported by any legislative history, legislative
comment, nor does the court point to comment sections from the
114 Id at 1153.
115 Id. See also Cal Health & Saf Code § 1635.2 (2006).
116 Cal Health & Saf Code § 1606.
117 Cryolife, 110 Cal App 4th at 1150.
118 Cal Health & Saf Code § 1606.
119 Cryoife, 110 Cal App 4th at 1155.
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Health and Safety Code. Instead, the court offers that the legis-
lature (in 1991) should have known or predicted that in 2003
"tissue banks are paid for their activities in connection with pro-
viding human cadaver tissue for medical use" and thus must
have "intended tissue banks to be immune from strict liabil-
ity."120 The court errs here as the legislature instead would have
been aware of the 1984 National Organ Transplantation Act,
which prohibits the buying and selling of body parts, including
human tissues.
However, the court's effort to be guided by the legislature is
undermined by the very judicial activism that it seems to reject,
but actually embraces.' 2 ' To explicate, the court extends immu-
nity protection to tissue banks when the statute that it relies
upon fails on its face to grant that type of protection to the indus-
try.'22 Without citation to studies, cases, or other data that would
support such a conclusion, the court crafted a new immunity
provision for tissue banks. The court gives a new and unusual
application of the tissue bank statute, which does not provide
any immunity language, without an effort to investigate or ex-
plain if the legislature actually intended for tissue banks to be
immune from strict liability lawsuits. It is more common to look
at the legislative history, or at least to examine the record of the
legislative committee enacting the statute when a case is under
de novo review. Had the court examined the legislative history of
the blood bank statute and the later tissue bank regulations, it
might have discovered that the public policy rationales for blood
bank immunity were quite unique to that industry.
Blood banks in the 1950s were mostly not-for-profit and of-
ten connected with hospitals. Legislatures treated the collection,
processing, storage, and administration of blood as a service and
not as a sale subject to warranty because blood banks were or-
ganized around altruistic principles, which were consistent with
their not-for-profit status. The legislative intent was to promote
the procurement of blood and protect blood banks from the possi-
bility of frivolous (and more serious) lawsuits. Blood supply was
vital as a domestic and military issue given cold war aggressions
and wars in Korea and later Vietnam. Blood banks were not in
the position to warrant the quality of blood that donors provided
despite the fact that they processed, transported, and adminis-
120 -Id.
121 Id at 1153-55.
122 Id.
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tered blood; they were limited by the available science at the
time. Nor was the technology available to perform sophisticated
blood analyses. Thus viruses transfused through blood were of-
ten undetectable during this era.
Tissue banks, on the other hand, are a different business
and social concept. While some tissue banks supply heart valves,
others focus on cosmetic services, such as products to enhance
lips, penis size, cheekbones, and other non-essential elective
medical products. Moreover, the technology is available for
highly sophisticated testing of tissues before they enter the
stream of commerce. The Cryolife court's grand leap leads one
only to guess what other industries would qualify for immunity
simply because they provide a medical service. Why not grant
immunity to the makers or providers of all medical devices, in-
cluding pacemakers, prosthetics, wheel chairs, and heart pumps?
The court too easily dismissed the plaintiff's claim that he
received a defective product and not a service. Minvielle's sur-
geon successfully implanted a contaminated body part. The ser-
vice received was perfectly fine. The product was the problem.
The court made a significant error in expanding the protection of
blood shield statutes (promulgated over forty years prior) 23 to an
industry neither so altruistic, nor anticipated by state legisla-
tures in the 1950s and 60s. Ironically, the court concludes its dis-
missal of the plaintiffs strict liability claim against a tissue bank
by quoting from an earlier blood shield law case, Hyland Thera-
peutics v Superior Court,'24 to support its rationale that the Cali-
fornia legislature intended for blood banks to be free from fault.
We concur in the perception that legislatures have deter-
mined that the production and use of human blood and its
derivatives for therapeutic purposes should be encour-
aged; and for this purpose those who provide these prod-
ucts, and who are themselves free from fault, should not
be required to bear the economic loss which might other-
wise be imposed under the rules of strict liability which
are applicable to sellers of commercial products gener-
ally.125
123 Cal AB 2209, 1991 Regular Session (March 8, 1991) in Cal Health and Safety Code
§ 1635.2 (West 2006). The 1606 statute discussed in the case goes back over forty years.
124 175 Cal App 3d 509 (Cal Ct App 1985).
125 Cryolife, 110 Cal App 4th at 1157.
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D. Indifference
The models discussed in Part I demonstrate that entrenched
formalism in a rapidly expanding biotechnological era will stymie
meaningful development of common law jurisprudence on the
ownership, dispensation, and remedies involving body parts.
Without judicial adaptation to an evolving society in which liti-
gation involves body parts, plaintiffs will never prevail. 26 A
common element of the three very different scenarios presented
in the above models is that absent a finding that deems the body
as "property," plaintiffs will be barred from recovery--even in the
more disturbing cases that involve the most egregious breaches
of medical trust and ethics. Formalistic rule making (or the lack
thereof), conflicts with reasoned, evolved decisionmaking. It fails
to acknowledge and respond to the shifting of culture, society,
and biotechnology. 127 Such rule making, "to put it baldly," accord-
ing to the Honorable Mary Schroeder, is to devise "pontifical
formulas which relieve [courts] of the burden of reasoned deci-
sionmaking."1
2s
The law too must evolve to address the nuanced byproducts
of biotechnology. Legislative and judicial indifference to the ways
in which biotechnology interferes with individual liberties, how-
ever, poses several serious problems.
1. Illusory negative rights.
For example, presumed consent legislation tramples indi-
vidual autonomy while purportedly designed to promote health
and safety. However, that worthy goal is defeated through sur-
reptitious tissue harvesting exclusively from unsafe victims, in-
cluding those whose deaths resulted from homicides, poisonings,
and other catastrophic means.'29 Failure to collect social history
126 See, for example, Moore, 793 P2d 479 (a case of first impression, rejecting conver-
sion claims for nonconsensual use of cells to develop a valuable patent). The majority
pointed out that Moore failed to cite a decision supporting his argument that the excised
spleen and cell line were property. Id at 489 n 28 ("[N]o party has cited a decision sup-
porting Moore's argument that excised cells are 'a species of tangible personal property
capable of being converted.'").
127 As even Moore illuminates, what was previously considered medical waste and
ordered to be incinerated (even by state statute) is now a patentable good. Id at 491.
128 Mary M. Schroeder, Fairness or Formulas, 1994 Wis L Rev 9, 9-10 (1994).
129 Four individuals became infected with AIDS after one Virginia Beach tissue bank,
LifeNet, sold tissues to 58 people in 16 states. The donor, who was shot and killed, had
also previously been infected with AIDS. Bill Sizemore, Body Parts: Big Business Medical
Advances And A Growing Willingness To Donate Organs Have Bolstered The Largely
Unregulated Trade Of Human Parts, The Virginian-Pilot Al (Apr 29, 2001). According to
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data increases the likelihood that insalubrious tissues will enter
the marketplace and harm those whom the statutes are designed
to protect. 13 The opt-out provision, as discussed earlier, is more
illusory than real. 3' The fact that there isn't a national or state
registry, except in Iowa, where one can opt-out of tissue donation
is a significant barrier.
States that enacted presumed consent laws failed to take
secondary measures to give full meaning to an individual or her
family's choice to decline extraction. Their failure to do so un-
questionably contributes to legal and social backlash against
presumed consent policies. 132 Thus, without a more serious effort
to capture assent or dissent, the opt-out provision is meaning-
less. Even in some instances when families refused to donate,
state actors successfully claimed immunity for the "accidental"
taking of tissues used for a legitimate state purpose. 133 Why then,
has formalism dominated judicial response to nonconsensual tis-
sue taking and the collateral outgrowths of biotechnology (in
other words, Model C)?
the author:
Organizations such as LifeNet list prices for 300 or more products. A kidney goes for
$19,000; a heart valve, $5,000; a 3-by-8-inch patch of skin, $144. Routinely, doctors
turn to these catalogs for tendons and ligaments to repair athletes' blown-out knees.
They buy arteries to improve circulation and valves to repair hearts. Cadaver bone
fragments are used in spinal fusion surgery on aging baby boomers' aching backs, or
ground into powder to replenish bone eroded away by gum disease. Skin is used to
treat severe burns. But plastic surgeons also use it to smooth out facial wrinkles, puff
up lips and enlarge penises.
Id.
130 See, for example, Michele Goodwin, Altruism's Limits: Law, Capacity, and Organ
Commodification, 56 Rutgers L Rev 305 (2004) (discussing the inefficiencies of the "pub-
lic" or legal method of obtaining body parts, and the "private" or black market method for
obtaining body parts); Ronald N. Robin, Elderly Heart Surgery Candidate with Concerns
about Transfusion: What's the "Take Home., Pearls from Clinical Cases, Consultant
1000 (July 1, 2003) (noting that "prior infections, such as ... Creutzfeldt-Jakob disease,
have been transmitted by donation of contaminated tissue, such as dura or cornea").
131 See, for example, Goodwin, Black Markets at 131-33 (cited in note 57).
132 See Newman v Sathyavaglswaran, 287 F3d 786, 789 (9th Cir 2002) (describing
removal of body parts from a decedent against the wishes of the decedent or their family
as a violation of fundamental human dignity); Brotherton v Cleveland, 923 F2d 477, 482
(6th Cir 1991) (referring to the presumed consent law in Ohio as "an egregious abuse of
government power").
133 See Alexa Boer and Steve Sternberg, Suit Filed Over Removal of Dead Girl's Or-
gans." Mother Says She Didn't Give Consent, Atlanta J Const B2 (June 15, 1991) (discuss-
ing a case where a mother consented to the removal of portions of the pelvic bone because
she was under the impression that doctors would remove only small and indiscernible
amounts, while large pieces were allegedly removed); Goodwin, 6 Va J L & Tech 2 (cited
in note 71).
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2. Episodic or collective.
Judges tend to view biotechnology cases involving body parts
episodically and not collectively.3 Viewed narrowly, Mr. Moore
seems to be one lone individual-a single plaintiff-with an iso-
lated case. His disease is rare and the defendants are located in
Los Angeles-their reach falls short of all other Moore-like pa-
tients at California's borders. It appears the instance will not be
repeated and the means justify the utilitarian ends; Moore pays
the emotional costs for a private industry gaining competitive
strength and furthering scientific understanding and possibly
engineering treatment options for a broader class of individuals
affected by leukemia. Here the California justices are responding
to a nationalist principle, an American advantage. Were the
company that collaborated with Dr. Golde a foreign corporation,
they may well have reached a different conclusion. Thus, the
case is not simply about the random expansion of biotechnology,
but specifically American technology. 135
3. Formalism entrenched.
Formalists necessarily ignore exogenous sources, instead
choosing to concentrate on adhering to traditional norms, 36 lest
they be viewed as unmindful of their role, radical or even judi-
134 Georgia Lions Eye Bank, 335 SE2d at 129 (opining "[c]ertainly, the General As-
sembly has it within its power, in the interest of the public welfare, to authorize this
procedure, which yearly benefits hundreds of Georgians"). Explained by Welch v Welch,
505 SE2d 470 (Ga 1998). Cited by State v Moseley, 436 SE2d 632 (Ga 1993); Schneider v
Susquehanna Radio Corp, 581 SE2d 603 (Ga Ct App 2003); Bauer v North Fulton Med
Ctr, Inc, 527 SE2d 240 (Ga Ct App 1999); Alternative Health Care Sys, Inc v McCown,
514 SE2d 691 (Ga Ct App 1999); Brotherton v Cleveland, 1992 US App LEXIS 15947 (6th
Cir June 30, 1992); Perry v Saint Francis Hosp & Medical Ctr, 886 F Supp 1551 (10th Cir
1995); Moore v Regents of University of California, 215 Cal App 3d 709 (Cal Ct App
1988), State v Powell, 497 So 2d 1188 (Fla 1986). Cited in dissenting opinion by Jackson
v State, 430 SE2d 781 (Ga Ct App 1993); Brotherton v Cleveland, 923 F2d 477, (6th Cir
Ohio 1991). Criticized by Mansaw v Midwest Organ Bank, 1998 US Dist LEXIS 10307
(WD Mo July 8, 1998); Newman v Sathyavaglswaran, 287 F3d 786 (9th Cir 2002).
135 Moore, 51 Cal 3d at 144 (describing the efforts of US researchers as "beginning to
bear fruit. Products developed through biotechnology that have already been approved for
marketing in this country include treatments and tests for leukemia, cancer, diabetes,
dwarfism, hepatitis-B, kidney transplant rejection, emphysema, osteoporosis, ulcers,
anemia, infertility, and gynecological tumors, to name but a few."). The court further
explains, "the extension of conversion law into this area will hinder research by restrict-
ing access to the necessary raw materials. Thousands of human cell lines already exist in
tissue repositories, such as the American Type Culture Collection and those operated by
the National Institutes of Health and the American Cancer Society." Id. See also Robert
Gatter, Walking the Talk of Trust In Human Subjects Research: The Challenge of Regu-
latingFinancial Conflicts of Interest, 52 Emory L J 327 (2003).
136 Calabresi, 55 Stan L Rev at 2115 (cited in note 23).
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cially activist. In essence, judges do not believe it is their role to
change the law to respond to biotechnology. They would argue
that it is the legislature's role to introduce new meaning to the
law; the courts simply sort out the statutory "mishmash."
1 37
Judge Guido Calabresi suggests that the formalist approach
"does not contemplate the introduction of new or modified values
into the scheme as part of the[ir] role." 13' Thus the court's func-
tion to hear the new biotechnology cases with an objective ear is
usurped not by judicial indifference to plaintiffs, but rather a
defense "of the values it finds embedded in the system."3 9 In
strictly adhering to formalism, judges ignore the independence of
the bench and its secondary function, which is to sort out the
mishmash. Obsequious loyalty to doctrine necessarily inures
heightened blindness to external factors, and in the face of bio-
technological harms to plaintiffs, may undermine the perception
of the judiciary as an independent, fair, competent arm of the
government.
Although Calabresi suggests that today's formalists "take a
bow to exogenous values," Models A-C (and there are many more)
do not support that conclusion. Rather, the refusal to tamper
with almost biblically derived notions of the body by introducing
new values, recognizing alternative paradigms and hermeneu-
tics, suffocates the law. Thus, while the law of body parts could
be a robust representation of nuanced thinking on a very com-
plex issue, instead it appears weak, ragged, and arbitrary.
II. PROTECTING GOLIATH: THE FEAR OF RETARDING
BIOTECHNOLOGY
The ramifications of recognizing and enforcing a property
interest in body tissues are not known, but are greatly
feared-the effect on human dignity of a marketplace in
human body parts, the impact on research and develop-
ment of competitive bidding for such materials, and the
137 See, for example, Moore, 793 P 2d at 493 (noting that "it is inappropriate to impose
liability for conversion based upon the allegations of Moore's complaint [because] prob-
lems in this area are better suited to legislative resolution").
138 See Calabresi, 55 Stan L Rev at 2115-16 (cited in note 23) (explaining four domi-
nant legal schools of thought: doctrinalism or autonomism, 'law and .. ', legal process
school, and law and status).
139 Id.
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exposure of researchers to potentially limitless and un-
charted tort liability.
140
One pattern that seems clear among Models A-C in Part I is
judicial deference to the furtherance of biotechnology, or a fear of
retarding the industry's growth by reaching outcomes that dis-
serve biotech interests. 141 Likewise, some commentators caution
against the commodification of body parts specifically because it
might threaten the growth of biotechnology in the United
States.142 Their opposition has little to do with respect for per-
sonhood or ideals about sacredness of the body.143 Rather, com-
mentators interested in the advancement of biotechnology are
concerned about the impact of litigation undermining the per-
manence, reputation, and financial stability of the biotech indus-
try-and so are the courts.'" Justice Arabian's concurrence in
Moore v Regents speaks directly to the "impact on research and
development" and the desire to avoid the potentially "limitless"
litigation against biotech firms. 145 Justice Arabian and the major-
ity's approach was one of deflection, finding that with avoidance
140 Moore, 793 P 2d at 498 (Arabian concurring). Justice Arabian's passionate concur-
rence shares the outrage of the dissenting justices, but stops short of offering a substan-
tive remedy for Moore. Arabian's concurring opinion is very concerned with the sacred-
ness of the body. He distinguishes Moore from prior holdings requiring courts to grapple
with indelicate subject matter, by suggesting that "the difference here, however, lies in
the nature of the conflicting moral, philosophical and even religious values at stake, and
in the profound implications of the position urged." Id.
141 Id.
142 Kevin Oberdorfer, The Lessons of Greenberg: Informed Consent and the Protection
of Tissue Sources' Research Interests, 93 Geo L J 365, 366 (2004) ("[C]ase law does not
support a common-law duty to disclose a researcher's commercial interests in tissue-
based research. Because no such duty exists, claims for failure to obtain informed consent
cannot be used by tissue sources and disease advocacy organizations to exert control over
intellectual property rights to tissue-based research.").
143 Id.
144 See Natasha N. AlIjalian, The Role Of Patent Scope In Biopharmaceutical Patents,
11 BU J Sci & Tech L 1 (2005) (arguing that biopharmaceutical patents should be limited
in scope so as to encourage research and investment); Brandon White, Protecting Patent
Owners From Infringement By The States: Will The Intellectual Property Rights Resto-
ration Act Of 1999 Finally Satisfy The Court 35 Akron L Rev 531 (2002) (arguing that
sovereign immunity mitigates the effectiveness of the patent system); Lisa J. Raines, The
Mouse That Roared: Patent Protection for Genetically Engineered Animals Makes Legal,
Moral, and Economic Sense, Issues Sci & Tech 64 (1988); Reid G. Adler, Controlling the
Applications of Biotechnology: A Critical Analysis of the Proposed Moratorium on Animal
Patenting, 1 Harv J L & Tech 1 (1988) (arguing that technology will help to engineer
safer and better foods, and that a moratorium on the patentability of living things will
have serious negative consequences without much gain). But see Gloria Banks, Legal &
Ethical Safeguards: Protection Of Society's Most Vulnerable Participants In A Commer-
cialized Organ Transplantation System, 21 Am J L & Med 45 (1995) (discussing the ethi-
cal implications of a commercial organ transplant system).
145 Moore, 793 P 2d at 498.
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of the conversion claim at issue an aspect of Moore's case could
survive based on breach of fiduciary duty.146 Arabian regarded
the court's deflection of the conversion claim as "a mark of wis-
dom." 4 7 After all, he conjectured, "courts cannot and should not
seek to fashion a remedy for every 'heartache and the thousand
natural shocks that flesh is heir to.'"14 Such risk averse deci-
sionmaking by courts with regard to biotechnological claims in-
volving body parts may ultimately undermine plaintiffs' confi-
dence in the neutrality of the judiciary.'49 The Moore case also
illuminates the underlying conflicts of interests that shadow bio-
technology cases in general. 5 '
A. Conflicting Interests Not Resolved By Moore
In each Model, there is an inherent conflict of economic in-
terest. Conflicts of interest appear to be the outgrowth and col-
lateral burdens of privatized biotechnology, particularly in the
sphere of body part procurement and distribution. 5' Consider
146 Id.
147 Id.
148 Id at 498 ("Sometimes, the discretion of forbearance is the better part of responsive
valor. This is such an occasion.").
149 See Danielle Wagner, Property Rights in the Human Body: The Commercialization
of Organ Transplantation and Biotechnology, 33 Duquesne L Rev 931, 942 (1995) (agree-
ing with the dissent in Moore that there is a legally cognizable property interest in the
body, and that a researcher's ability to profit by defrauding a medical patient violates the
principal of unjust enrichment).
150 See, for example, Jose Cardo, Former Lifequest (FL) Organ Recovery Director
Arrested On Charges Of Selling Organs To His Own Company, 13 Transplant News (Apr
14, 2003) (noting that most body parts are donated for "noble," altruistic reasons, while
those who accept donations can be motivated by profits); Gatter, 52 Emory L J at 331
(cited in note 135) (noting that "as with abuses of trust among accountants, corporate
executives, and priests, there has been a call for new rules to prevent the erosion of trust
in the human research enterprise"); Lars Noah, Medicine's Epistemology: Mapping the
Haphazard Diffusion ofKnowledge in the Biomedical Community, 44 Ariz L Rev 373, 395
(2002) (noting that conflicts of interest now "permeate medical literature"); Cynthia Ho,
Who Deserves The Patent Pot Of Gold?." An Inquiry Into The Proper Inventorship Of
Patient-Based Discoveries, 7 DePaul J Health Care L 185, 197-202 (2004) (discussing
medical researchers commercial interests and patients typical unawareness of that inter-
est); Emily J. Schaffer, Is the Fox Guarding the Henhouse? Who Makes the Rules in
American Nutrition Policy, 57 Food Drug L J 371 (2002) (asserting that the government
often faces conflicts of interests between individual interests and public interests, specifi-
cally regarding nutrition policy).
15' See Jim Warren, Stolen Body Parts Scandal Generating Gruesome Headlines,
Fears of Infection; NY Grand Jury Meeting, Transplant News (Jan 13, 2006) (describing
the recent scandal in New York and New Jersey involving funeral homes selling bones
and other body parts to brokers who then resell the body parts for thousands of dollars);
In Wake Of National Body Part Transplant Scandal, Schumer To Unveil Critical Legisla-
tion To Regulate Yssue Transplants, States News Service (Jan 23, 2006) available at
<http'//www.senate.gov/-schumer/SchumerWebsite/pressroom/pressreleases/2006/PR18.
Transplant.012306.html> (discussing a New York Senator's call for increased regulation
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the recent flux of proposed legislation and investigation into body
part selling from funeral homes in New York and New Jersey.
One commentator reports:
A grand jury in Brooklyn was hearing evidence against
the suspected source of the tissue, Biomedical Tissue Ser-
vices Ltd. of Fort Lee, N.J., the Associated Press reported
last month. Operating in New York City, company repre-
sentatives may have procured bone, skin and tendons
from the bodies of people who were not signed up to be tis-
sue donors .... There is suspicion that records were forged
to make the procured parts more profitable through such
moves as changing the cause of death from cancer, a dis-
qualifying condition, to heart attack. It's illegal to procure
body parts without consent and to sell them for a profit. 52
That Dr. Golde, in the Moore case, and his research team
had conflicted loyalties is indicated in the court's holding.1 3 The
court limits Moore's remedy to breach of fiduciary duty because
Golde failed to inform him about the pecuniary projects associ-
ated with the exploitation of the excised spleen and cells.' In
support of this limited remedy, Justice Panelli concludes that
Moore should have been able to go elsewhere-namely, to a doc-
tor who would not defraud him. This is true enough but less real-
istic given the scope of the doctrine elucidated by the majority.
Does Moore really have the "option" to seek unbiased medical
assistance elsewhere? Given the model left by the court, it is
of the tissue transplant industry); Jeff Sturgeon, Possibly Stolen Body Parts Find Way to
Carion, Roanoke Times Al (Jan 7, 2006) (investigating the possible link between stolen
tissues and bones in New York and those purchased by Carilion). The author noted that
there were safety concerns as well: "Carilion buys from one affected company, LifeCell
Corp., a manufacturer of reconstructive, urogynecologic and orthopedic surgical products,
and had received merchandise from a lot of goods deemed suspect because the lot was
manufactured or might have been manufactured using raw material from Biomedical
Tissue Services." Sturgeon, Possibly Stolen Body Parts Find Way to Carilion, Roanoke
Times at A1 (cited in note 151).
152 Sturgeon, Possibly Stolen Body Parts Find Way to Carilion, Roanoke Times at Al
(cited in note 151).
153 See, for example, Moore, 793 P2d at 481 (noting that Moore 'can make an informed
decision to consent to treatment, or to withhold consent and look elsewhere for medical
assistance"). However, it is absurd to think that other researchers would not also seek to
exploit Moore's body in general and cell line in particular given the very unique opportu-
nity presented by his case. If Moore is told that death is imminent without an operation,
but physicians insist upon keeping and profiting from Moore's body parts, (which raises
an issue about the veracity of medical statements that suggest medical intervention is
necessary) or refuse to perform the operation, Moore is left to deal with a quid pro quo.
The majority fails to acknowledge this.
'5 Id at 485.
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more illusory than real to suggest that Moore can go anywhere
he wants for the operation-or a surgical procedure free from
financial conflicts between the physician and patient. Rather
than crafting a rule that discourages or strongly disfavors the
underlying coercion, deception and fraud, the court has simply
placed an economic burden on that activity. Deception is "incen-
tivised" in the formalist approach to adjudication of biotechnol-
ogy disputes.
If manipulating Moore and his cell line are worth over $3 bil-
lion dollars,' and the risk of litigation and possible loss will cost
only $250,000,156 then it seems economically prudent to lie to and
deceive patients and research subjects like Moore. When viewed
in economic terms, the cost of litigation inures significant benefit
to defendant biotechnologists; the biotech industry has been
spared the potential loss of billions of dollars as a result of for-
malist decisionmaking. Further, the Moore court's strict adher-
ence to doctrinalism or prior law creates a prophylactic veil of
protection for the biotech industry, particularly in California.'57
One can regard the limited remedy for Moore as providing a fi-
nancial windfall and protection for the defendants. The court's
ruling that plaintiffs are not entitled to economic relief when
their body parts are fraudulently obtained was worth the payout
to Mr. Moore as it protects an entire research industry.'58
155 The complaint in Moore alleged that "the true clinical potential of each of the lym-
phokines ... [is] difficult to predict, [but] ... competing commercial firms in these relevant
fields have published reports in biotechnology industry periodicals predicting a potential
market of approximately $3.01 Billion Dollars by the year 1990." Id at 482.
156 See Mehlman, The Story of Moore v. Regents of the University of California at 53
(cited in note 29) (discussing California's limitations on medical malpractice recovery).
Moore's claim would be limited according to California's medical malpractice reform,
which "limits damages to actual losses plus a maximum of $250,000 for pain and suffer-
ing." Id.
157 Moore is regarded as the seminal case of the biotechnology era. Some scholars
consider the case to be a "classic" in the field of property. For example, Gerald Korngold
and Andrew P. Morriss refer to the case as the "brave new frontier of property-given
that human tissues and other by-products now have commercial value." Gerald Korngold
and Andrew P. Morriss, eds, Property Stories 4 (Foundation 2004). In their book, Prop-
erty Stories, Moore is one of the most substantive property cases to be discussed. Id.
15' Numerous cases now cite Moore for the proposition that plaintiffs have no property
interests in their body parts nonconsensually removed, removed under duress or fraud, or
body parts purchased for implantation. See, for example, Ananda Church of Self-
Realization v Mass Bay Ins Co, 95 Cal App 4th 1273, 1282 (Cal App 2002); Miles, Inc v
Scripps Cinic and Research Foundation, 810 F Supp 1091, 1095 (S D Cal 1993); Kremen
v Cohen, 325 F3d 1035, 1040 (9th Cir 2003). The reach of Moore and its progeny of cases
is quite extensive. One of its legacy cases, Cryolife v Superior Court, although a relatively
recent adjudication, has already been cited thirteen times in treatises for the proposition
that tissue banks sell services and not products, extending the misguided notion that the
tangible items bought and sold by tissue banks are simply services. See, for example, 1
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The court's ambitious claim that similarly situated univer-
sity researchers, physicians, or tissue banks will find the Moore
holding to be a deterrent demonstrates the majority's naivet6
with regard to the power of unregulated biotechnology.5 9 Evi-
dence that the case has had little impact on enhancing informed
consent or heightening attention to fiduciary duties is easily
gleaned from recent controversies 161 involving universities selling
cadavers and body parts to tissue banks,161 coroner offices work-
ing intimately with tissue banks,1 62 funeral homes and cremato-
California Courtroom Evidence 452; 15-177 California Forms of Pleading and Practice-
Annotated 177.51; 40-460 California Forms of Pleading and Practice-Annotated 460.11;
40-460 California Forms of Pleading and Practice-Annotated 460.104; 17-175 California
Points & Authorities Form 43; 19-190 California Points & Authorities Form 11.1; 1-2
California Products Liability Actions 2.14; 3-31 California Torts 31.02; 1-8 Products Li-
ability Practice Guide 8.01; 2-10 Drug Product Liability 10.05; 2-14 Drug Product Liabil-
ity 14.06; 1-1 Products Liability 1.07; 2-20 Punitive Damages 20.1 (Cont).
There is a diverse line of cases that all cite Moore and limit plaintiffs relief against
tissue banks, coroners, physicians like Dr. Golde, and others involved in contemporary
biotechnology. See, for example, Greenberg v Miami Children's Hasp Research Inst, Inc,
264 F Supp 2d 1064, 1074 (2003) (citing Moore for the proposition that plaintiffs had no
property interests in the genetic material they supplied to doctor for specific purpose of
finding cure to disease affecting their children when physician failed to inform them of
his research developments and patent based on their genetic material); Condos, 208 F
Supp 2d at 1226 (reasoning transplant of bone tissue held not to be a sale of product for
purposes of strict liability, holding in part that the contaminated body part is not prop-
erty nor a product when bought by a patient); Cryolfe, 110 Cal App 4th at 1145 (opining
that for-profit tissue bank provides a service when it sells body parts, not a product be-
cause the body is not property); Perry v Saint Francis Hosp & Medical Ctr, 886 F Supp
1551, 1563 (D Kan 1995) (concluding that plaintiffs lacked property right in the body of
relative whose organs were harvested pursuant after misinformation provided by nurse);
Miles, Inc v Scripps Clinic & Research Found, 810 F Supp 1091, 1095-96 (S D Cal 1993)
(holding there was an intangible property interest in the commercialization of a cell line,
but declining to extend California law to recognize a cause of action for conversion of that
interest).
159 The majority clarifies that Moore does have a right associated with his cell line.
According to the court, "a fully informed patient may always withhold consent to treat-
ment by a physician whose research plans the patient does not approve." Moore, 793 P 2d
at 492.
160 See Goodwin, Commerce in Cadavers is an Open Secret, LA Times at B15 (cited in
note 16); Skloot, Taking the Least of You, NY Times Mag at 38 (cited in note 91) (discuss-
ing pending lawsuits involving questions of ownership and proprietary interests); Ron
Nissimov and Kevin Moran, The Body Business: Demand High for Tissues, Organs,
Houston Chron Al (July 7, 2002) (discussing recent misappropriations of donated body
parts to various institutions); Michael Fisher and Sandy Stokes, Body Parts a Brisk Mar-
ket, The Press Enterprise A01 (Mar 3, 2002) (discussing the lack of regulation of
"[c]ompanies trading in human parts" and the resulting in the removal of parts from
decedents without permission of the families).
161 Tom Henderson, Company Taps Research Boom, Detroit News 4B (Apr 17, 2005);
James T. Mulder, Body Parts, Tissue Collection Big Business in CN, Post-Standard
Al (Feb 27, 2005); Anne Belli, Families of Donors Rarely Get Full Story, Houston Chron
A01 (Feb 13, 2005).
162 See, for example, Ron Seely, Tissue Bank Criticized for Offer of Trip to Coroners,
Wisc St J (Aug 27, 2005) (discussing a free three-day trip to Las Vegas that was offered
by tissue bank to coroners and medical examiners); Frammolino, Harvest of Corneas, IA
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riums selling body parts to brokers,'163 and organ procurement
organizations channeling donated body parts to for-profit tissue
banks.'" Much can be gleaned from recent headlines across the
United States: "A Dispute Over Brain Donations; Families Allege
Improper Consent in Lawsuits Against Bethesda Institute"165 ;
"Former Lifequest (FL) Organ Recovery Director Arrested On
Charges Of Selling Organs To His Own Company"'66 ; "UW Organ
Audit Cites Coziness, Bad Records" 6 v; "Little Shop of Horror"68;
"Massachusetts: 'Secret' Tissue Bank Contract Questioned"' 69;
"Med Examiner's Office Has Secret Body-Parts Deal: Conflict
Eyed In M.E., Tissue Bank Pact v0; "Grief Counselors At Morgue
Funded By Transplant Group Some Have Qualms About Part-
Times at Al (cited in note 49) (exposing the harvesting and selling of cadaver tissues at
coroner's office to tissue banks at tremendous profits).
16 See Michael Brick, At a Brooklyn Funeral Home, an Investigation Considers the
Macabre, NY Times B3 (Oct 31, 2005) (discussing a criminal inquiry into whether an
embalmer was removing body parts and selling them); Ellis Henican, Bone-Rattling
Scandal, Newsday A8 (Jan 6, 2006) (discussing one allegation of a funeral home removing
bones and selling them on the black market); Samuel Bruchey, Her Fearful Discovery,-
North Shore LIJ Patient, Among 42 Notified Of Possible Faulty Transplants, Says She
Has Syphilis, Newsday A8 (Jan 5, 2006) (discussing Patricia Battisti's contraction of
syphilis from tissue used in her bone graft that might not have been screened for dis-
eases).
164 See Jose Cardo, Former Lifequest (FL) Organ Recovery Director Arrested On
Charges Of Selling Organs To His Own Company, 13 Transplant News (cited in note 150)
(exposing the conflicts of interests inherent in modern biotechnology where director of
tissue recovery for an organ procurement organization began siphoning the body parts to
the tissue bank that he owned); St. Jude Medical to Focus on Future of Cardiac Surgery
and Surgical Ablation at Annual Meeting of the Society of Thoracic Surgeons, Bus Wire
(Jan 26, 2006) (pointing out that biotechnology companies are "moving to the future,"
reporting "[a]lready the exclusive distributor of LifeNet's cardiac allograft products, St.
Jude Medical has recently extended its agreement with LifeNet-the nation's largest full
service organ procurement organization and tissue-banking system-to include exclusive
distribution of vascular allografts for use in cardiac applications"); In Wake Of National
Body Part Transplant Scandal, Schumer To Unveil Critical Legislation To Regulate Tis-
sue Transplants, States News Service (Jan 23, 2006); Patricia Simms, Organ Program
Not Monitored, Wisc St J 1A (Aug 19, 2000).
165 David Snyder, A Dispute Over Brain Donations; Families Allege Improper Consent
in Lawsuits Against Bethesda Institute, Wash Post B1 (June 30, 2005).
166 Jose Cardo, Former Lifequest (FL) Organ Recovery Director Arrested On Charges
Of Selling Organs To His Own Company, 13 Transplant News (cited in note 150).
167 Aaron Nathans, UW Organ Audit Cites Coziness, Bad Records, Capital Times 2A
(Aug 19, 2000).
168 Katy Vine, Little Shop of Horrors, Texas Monthly 90 (Aug 2003) (reporting on the
macabre enterprise of body procurement specialist employed by a Texas university who
began funneling the body parts to his private company, which he opened after realizing
how lucrative selling human tissue and body parts can be).
169 Massachusetts: 'Secret' Tissue Bank Contract Questioned, American Health
Line (May 21, 2002).
170 Tom Mashberg, Med Examiner's Office Has Secret Body-Parts Deal, The Boston
Herald 001 (May 20, 2002).
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nership"171; "Organ Procurement Chief Resigns; He Took Pay
From Tissue Banks He Did Business With, Investigation
Shows" 172 ; and "FDA Cracks Down on Seattle Tissue Bank:
Agency Targeting Use of Suspected Contaminated Body Parts."73
In Moore, if the defendants had no overriding moral objec-
tions to deceiving a patient, surreptitiously harvesting and pat-
enting the derivatives from human life, then what moral objec-
tions would they have to nondisclosure of financial interests? The
penalty for exploiting Moore is infinitesimal compared to the lu-
crative incentives to deceive him.'74 Justice Panelli's majority
ruling in Moore essentially established a tax; John Moore's pay-
off for Dr. Golde's breach of informed consent was the fee for do-
ing business. In the larger scheme it was a small price to pay.
The incentive crafted by the court is to exploit human research,
even if it means harming vulnerable subjects. The court presents
no clear disincentives to curtail physicians' and researchers'
breaches of duty here. The notion that Moore can shop for other
physicians who will be less interested in the recognition, reward,
tenure, publications, and research opportunities derived from
Moore's unique case is fundamentally out of touch with academic
research and university promotion and reward policies in gen-
eral. 7 '
Yet, we need not focus exclusively on the conflicts of interest
that arise out of the Moore case; its progeny also create an inter-
171 Sally Farhat, Grief Counselors At Morgue Funded By Transplant Group Some
Have Qualms About Partnership, Detroit Free Press B6 (Apr 12, 2001).
172 Patricia Hoftiezer Simms and Andy Hall, Organ Procurement Chief Resigns; He
Took Pay From Tissue Banks He Did Business With, Investigation Shows, Wisc St J
Al (May 13, 2000).
173 Tom Paulson, FDA Cracks Down on Seattle T'ssue Bank: Agency Targeting Use of
Suspected Contaminated Body Parts, Seattle Post-Intelligencer Al (Apr 12, 1995).
174 It is estimated that the cell line derived from John Moore is worth billions of dol-
lars. Moore, 793 P2d at 482. Beyond the future value derived from Moore's cell line, the
defendants recouped immediate benefits:
With the Regents' assistance, Golde negotiated agreements for commercial devel-
opment of the cell line and products to be derived from it. Under an agreement
with Genetics Institute, Golde "became a paid consultant" and "acquired the rights
to 75,000 shares of common stock." Genetics Institute also agreed to pay Golde and
the Regents "at least $330,000 over three years, including a pro-rata share of
[Golde's] salary and fringe benefits, in exchange for ... exclusive access to the ma-
terials and research performed" on the cell line and products derived from it.
[Later] Sandoz 'was added to the agreement" and compensation payable to Golde
and the Regents was increased by $110,000.
Id.
175 See Gatter, 52 Emory L Journal at 331, 344 (cited in note 135) (discussing influ-
ence commercial interests in health research, and the pervasiveness of such influence).
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esting body of case law. Consider for example the conflicting in-
terests of Georgia Lion's Eye Bank176 and its thorny relationships
with entities that buy tissues it harvests at huge mark-ups. Or
consider attempts by Cryolife,117 a financially successful, aggres-
sive, corporation, 7 8 to reject industry health and safety stan-
dards, despite a spate of illnesses resulting from the implanta-
tion its contaminated products.1 79 According to the Georgia dis-
trict court, although Cryolife's processing protocols are detailed
and specific, "they are not as rigorous as other tissue banks." 8 '
Cryolife procures cadavers that are rejected by other tissue
banks, including unrefrigerated corpses and dead bodies of sui-
cide victims usually rejected because the time of death is difficult
to establish.' 8 ' Cryolife accepts cadavers of persons with menin-
gitis, cancer, and other diseases and reprocesses and sells them
to unwitting patients at a significant mark-up and profit mar-
gin.18 2 Thus, the notion that the biotech industry is an effective
self-regulator of patients and plaintiffs' interests stretches real-
ity and belies the truth. Moreover, placing such a burden on the
nascent industry to police itself and establish equitable norms
seems untenable given the mixed social motivation to encourage
industry and yet protect research subjects.
Accordingly, financial conflicts of interests in the biotechnol-
ogy industry must be placed in context. 8 3 According to Robert
176 See Boer and Sternberg, Suit Filed Over Removal of Dead Girl's Organs: Mother
Says She Didn't Give Consent, Atlanta J and Const B2 (cited in note 133) (discussing the
allegations against the Georgia Lions Eye Bank, that they mutilated a woman killed in a
car accident and removed her body parts without proper consent).
177 Cryolife Heart Valve Patients Cry Foul, CBS News (Aug 27, 2002) available at
<http'//www.cbsnews.com/stories/2002/08/27/eveningnews/main519937.shtm> (last vis-
ited Oct 22, 2005).
178 See In re Cryolife, Inc Securities Litigation, 2003 US Dist LEXIS 26170 (N D Ga).
James Paton, Cryolife Defendants Settle Claims, Rocky Mountain News B12 (Sept 16,
2005) (discussing a settlement by Cryolife managers for engaging in illegal trading);
Cryolife Inc. Agrees To $23 Million Settlement To End Shareholder Suit, Securities Class
Action Reporter 8 (Aug 15, 2005).
179 Cryolife is quick to defend its company by suggesting that the spate of illnesses
and deaths resulting from its processed tissues are unique and rare cases. See, for exam-
ple, Peralte C. Paul, Cryolife Stock Falls After Another Tissue Problem; Not Alarmed:
Analyst Says Case Unfortunate, But Doesn't Expect A Serious Problem For The Com-
pany, Atlanta J and Const 3F (Dec 6, 2003) (providing Cryolife's response to a teenage
boy developing an infection originating from tissue sold by Cryolife).
180 See In re Cryol'fe, Inc Securities Litigation, 2003 US Dist LEXIS 26170 (N D Ga).
181 Id.
182 Id.
183 Charlotte H. Harrison, Neither Moore nor the Market: Alternative Models for
Compensating Contributors of Human Tssue, 28 Am J L and Med 77 (2002); Consider
Sonia M. Suter, Dhsentangling Privacy from Property: Toward a Deeper Understanding of
Genetic Privacy, 72 Geo Wash L Rev 737 (2004) (noting the "rush to commercialize tissue
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Gatter, "financial conflicts of interest are an outgrowth of federal
technology transfer policy, which has successfully employed
market incentives to make researchers and their institutions
more responsive to the needs of corporations creating medical
products."1"4
B. Knocking Down Goliath: Fear of Endangering Biotech Gi-
ants
That the social goals of most legislative enactments may also
burden individuals while benefiting the general welfare, is
hardly an untested concept. 8 5 Thus, to some extent legislators
may have anticipated the thorny landscape created by a near
deregulation of biotechnology, including the need to clarify proto-
cols involving research subjects, emerging conflicts of interests
between researchers and their universities, and managing finan-
cial conflicting interests.1 8 6 Yet, it also seemed likely that Con-
gress purposefully left these hefty issues to the courts for resolu-
tion.
The Bayh-Dole Act 8 7 and the Stevenson-Wydler Technology
Innovation Act 8 8 were specifically enacted to promote the devel-
opment of science and biotechnology by purposefully permitting
the fruit of publicly funded research to become the private intel-
lectual property of researchers, universities, and their affili-
banks"); Donna M. Gitter, Ownership of Human Tissue: A Proposal for Federal Recogni-
tion of Human Research Participants' Property Rights in Their Biological Material, 61
Wash and Lee L Rev 257 (2004).
184 See Gatter, 52 Emory L J at 334 (cited in note 135) (arguing that one must under-
stand the political and economic context of human research subjects in order to fully
understand financial conflicts of interest therein).
185 The Bayh-Dole Act of 1980 was enacted to "encourage greater production of com-
mercially valuable research." See id at 335; Bayh-Dole Act, Pub L No 96-517 § 6(a), 94
Stat 3015, 3019-28 (1980), 35 USC §§ 200-212 (2000) (the Act attempts to provide incen-
tives for collaboration among private and public researchers).
186 The Office of Technology Assessment warned Congress, emphasizing "uncertainty
about how courts will resolve disputes between specimen sources and specimen users
could be detrimental to both academic researchers and the infant biotechnology industry,
particularly when the rights are asserted long after the specimen was obtained. The as-
sertion of rights by sources would affect not only the researcher who obtained the original
specimen, but perhaps other researchers as well." Moore, 793 P 2d at 493 (citing U.S.
Congress, Office of Technology Assessment, New Developments in Biotechnology: Owner-
ship of Human Tissues and Cells 31-46 (1987)).
187 See Bayh-Dole Act, 35 USC §§ 200-212.
18 See Stevenson-Wydler Technology Innovation Act of 1980, Pub L No 96-480, 94
Stat 2311 (1980) (the Act attempts to promote technology by establishing organizations in
the executive branch to stimulate technology, establish centers for industrial technology,
and recognize individuals who have made outstanding contributions to technology).
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ates. 89 To legislators, perhaps, the ends would justify the means.
In other words, global market advantage in biotechnology was
expected to benefit our society, perhaps through the development
of effective drugs to treat illnesses, increased scientific knowl-
edge, and improved the status of the United States among na-
tions engaged in biotechnology. Members of Congress likely pre-
dicted that a successful biotech industry would stimulate eco-
nomic growth, development, and investment in the United
States.190
Their predictions were correct; "all indications are that by
privatizing the ownership of scientific research results, Congress
effectively created the 'technology transfer' market, designed to
speed the transformation of science to commercial products."191
Biotechnology is arguably the most rapidly expanding sphere of
the U.S. economy1 92; biotech companies, for better or worse, are
well integrated into the university structure, and products rang-
ing from the therapeutic (for example, regenerative skin for burn
victims) to cosmetic sex therapies and lip enhancements result
from this technology transfer. I would hardly argue that these
are negatives, but rather that these advancements must be un-
derstood for what they are and in context with the changing so-
cial and cultural landscape. In effect, courts must examine the
power dynamics between biotechnology and the individuals-the
society-it is to serve. Arguably, that relationship is now out of
balance (if it were ever congruent).
Biotechnology, in free reign, is perhaps different than rigor-
ously monitored technology with checks and balances. The differ-
ences between the two may have less to do with curbing innova-
tion than protecting the public from harm. That Congress
189 See Jerry Shottenkirk, Biomedical Research Has Become Big Business, Kan City
Daily Record (Jan 1, 2006) (discussing the purposes and effects of the Bayh-Dole Act);
Goldie Blumenstyk, Turning Research--Slowly-Into Riches, Chronicle of Higher Ed 44
(Oct 7, 2005) (comparing American and European approaches to allowing universities to
patent inventions developed by their professors).
190 Technology Commercialization Improvements Act of 1993, Hearing Before the
Subcommittee on Technology, Environment and Aviation of the House Committee on
Science, Space and Technology, 104th Cong, 2nd session (Sept 20, 1994) (prepared testi-
mony of Mary Lowe Good, Under Secretary of Commerce for Technology).
191 Gatter, 52 Emory L J at 336 (cited in note 135).
192 Karin Price Mueller, A Fund, an ETF and a Stock: 3 Investments to Consider Now,
The Star Ledger 7 (Feb 19, 2006) (predicting that "biotechnology should remain one of the
fastest growing areas of the economy"); Patricia Fischer, Richter Opens New Biotech Lab,
Budapest Business Journal (Nov 21, 2005) (noting that "[bliotechnology is the fastest
growing industry in the world"); Carving a Slice ofLucrative te, New Straits Times (Apr
28, 2005) (declaring that biotechnology is "one of the fastest growing markets in the
world").
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wanted biotechnology to thrive cannot in contemporary terms be
interpreted as granting the biotech industry immunity from judi-
cial scrutiny. Lori Andrews reminds us, "science is not the high-
est value in society."19
The rationales for unrestrained biotechnology are no longer
as persuasive today, nor do they correspond to the ways in which
individuals engage with biotechnology. In essence, there
were/are three very different goals that must be segregated. The
first goal is to promote biotechnology-lift it from its nascent po-
sition-to an independently thriving and robust industry. Be-
yond any doubts, this objective has been achieved. The second
goal, however, must be to protect individual/community liberty,
to promote safety from the harms and unintended consequences
of biotechnology. Finally, and likely most controversially, we
must rigorously monitor and when necessary harness unethical
pursuits in biotechnology. In this, of course, are lessons to be
learned from the excesses of prior biotechnological regimes, in-
cluding the perfidious exploitation of human subjects during the
holocaust and slavery in the United States.194 For some, the no-
tion of controlling biotechnology is to limit scientific creativity, to
stymie its development, and to unduly subject the industry to
meaningless bureaucracy. Those perceptions, while compelling
and sympathetic to the industry and those of us who find value
in markets, lose their appeal when tested over time, particularly
as it appears that biotechnology transfer overwhelms judicial
decisionmaking and there is, at best, limited legislative guid-
ance. Thus, I am increasingly convinced that to abjure all regula-
tion, judicially, professionally, or legislatively imposed on bio-
technology transfer, ultimately disserves the industry, impairs
the fluid development of jurisprudence, and undermines public
trust.
According to Professor Robert Gatter, there are two clear re-
sults of the technology transfer age. First, "universities and re-
searchers are filing patent applications in unprecedented num-
bers that appear to grow each year," and second, "private owner-
ship of research has spawned a new kind of corporation-the
faculty start up-through which researchers and research insti-
193 Skloot, Taking the Least of You, The New York Times Mag 43 (April 16, 2006)
(cited in note 91) (quoting Lori Andrews).
194 See Patricia Heberer, Lessons from the Holocaust: Law, Medicine and the Future
of Biotechnology, Lecture at the University Club of Chicago (Jan 25, 2006) (examining
how unregulated biotechnology and medical experimentation in Germany led to the abuse
of vulnerable populations) (on file with author).
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tutions exploit the commercial value of their research results."9 '
Yet, on the other hand, given the spate of recent criticisms levied
at the tissue banking industry and affiliated markets, legislators
may not have given full consideration to the extent to which the
human body would be exploited and commercialized through bio-
technology. This oversight creates its own gap in the law and as
a result courts are wisely bound to weigh the purpose and bur-
dens of legislation and not the current misgivings of individual
senators. 196
Courts back away from curing the allegations that biotech-
nology has gone too far. Rather, given their investment in a for-
malist approach to rule interpretation and reliance on judicial
precedent and legislative enactments, they often defer to bio-
technology. In Moore, after reaching the conclusion that the sub-
ject matter of the Regents' patent could not be Moore's property,
the court suggests that it would be unfair to encumber the bio-
tech industry with plaintiffs' claims.197 The majority declared,
"the extension of conversion law into this area will hinder re-
search by restricting access to the necessary raw materials." 98
Thus the court implies a biotech industry entitlement to human
materials. After all, if we are to rely on the majority's holding,
human materials would only be restricted from researchers' ac-
cess because doctors had failed to obtain consent or a patient
simply refused to surrender her body parts. It is here that the
court reveals its own misgivings that physicians, researchers,
and others in the biotechnology industry will act justly by reveal-
ing their research interests in their patients and informing the
same of their financial interests, which undergirds its holding.
Justice Panelli reaches a befuddling conclusion (in light of
recognizing Golde's breach of fiduciary duty), writing that an
"important policy consideration is that we not threaten with dis-
abling civil liability innocent parties who are engaged in socially
useful activities, such as researchers who have no reason to be-
lieve that their use of a particular cell sample is, or may be,
against a donor's wishes." 99 Pinelli's majority fashioned an un-
tenable remedy by recognizing a limited autonomy right (for
195 Gatter, 52 Emory L J at 336 (cited in note 135).
196 See Ridgely Ochs, Sen. Pushes Tissue Regulation, Newsday A15 (New York, NY)
(Jan 24, 2006) (discussing one senator's displeasure "to his call for more oversight of
tissue transplants").
19' Moore, 793 P2d at 493.
198 Id at 494.
199 Id at 493.
THE UNIVERSITY OF CHICAGO LEGAL FORUM
Moore) "without unnecessarily hindering research." 00 The court
explains that recognizing a legal status in the body might pro-
vide a remedy for plaintiffs, but would equally have broad and
likely negative impacts on biotechnology.20 '
The Moore court attempts to balance competing, but not ir-
reconcilable interests. The case is far more complex than tort and
property scholars have allowed; the fact that UCLA is a state
agent adds further nuance to the holding as well as its omissions.
First, the Moore court is concerned with promoting and protect-
ing incentives in conducting medical research. Second, the court
is apprehensive about crafting a rule that recognizes traditional
constitutional law claims in the context of body part theft, in-
cluding due process, breach of privacy, unwarranted searches
and seizures, and possibly First Amendment claims given possi-
ble violations of particular religious groups. Third, and perhaps
most obviously, the court is conflicted about whether random
research subjects such as Moore could destabilize biotech innova-
tion by introducing civil litigation as the mechanism for resolving
disputes with researchers and biotech companies as opposed to
seeking redress through other institutional processes.2 2 The
court concludes:
As in Brown, the theory of liability that Moore urges us to
endorse threatens to destroy the economic incentive to
conduct important medical research. If the use of cells in
research is a conversion, then with every cell sample a re-
searcher purchases a ticket in a litigation lottery. Because
liability for conversion is predicated on a continuing own-
ership interest, "companies are unlikely to invest heavily
in developing, manufacturing, or marketing a product
when uncertainty about clear title exists." In our view,
borrowing again from Brown, "it is not unreasonable to
conclude in these circumstances that the imposition of a
harsher test for liability would not further the public in-
terest in the development and availability of these impor-
tant products."2 3
200 Id at 494.
201 Moore, 793 P2d at 495.
202 Id. Compare Calabresi, 55 Stan L Rev at 2133-34 (cited in note 23) (listing the
rights that follow in a doctrinalist view that we do own our bodies as property).
203 Moore, 793 P 2d at 495-96 (citing Brown v Superior Court, 44 Cal 3d 1049, 1065
(1988)).
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Similarly, in another seminal case, Cryolife v Superior
Court, the court seems paralyzed by its ability to craft jurispru-
dence that responds to biotech malfeasance. The court does not
disturb Cryolife's enviable market position, nor impose account-
ability measures. °" Rather, the California Appeals Court ac-
knowledges that the tissue bank sells its goods, but refuses to
hold the company responsible for negligence and poor processing
standards, which violate industry norms.2"5 A sister court, hear-
ing a securities fraud case against Cryolife noted that, "[i]n addi-
tion to [Cryolife's] procurement of cadavers and tissue with a risk
of contamination, Cryolife, unlike other tissue processors, does
not test its tissues for contamination prior to processing. Before
1997, Cryolife pre-tested its tissues; however, Cryolife discontin-
ued this process in an effort to save money."2"6 From a plaintiff's
perspective, where will checks and balances come from if the leg-
islature defers to the judiciary and the courts decline to develop
jurisprudence that could erect guideposts?
Let us consider the Cryolife v Superior Court ruling and its
important application in to biotechnology disputes. First, the
court grants relief to a for-profit tissue company based on blood
shield law immunity, which traditionally protected not-for-profit
blood banks.2 7 The majority misreads the blood shield statute
and extends its application to a tissue bank. The court then
makes an incongruous comparison between hospitals and tissue
banks. It correctly asserts, "[t]he rationale for the blood shield
law is that the supplying of blood by a hospital to a patient is
'merely incidental' to the services rendered by the hospital."20 8
Yet how the court reaches the conclusion that a for-profit tissue
bank fits into that analysis is a mind leap. To be clear, while sup-
plying blood may be an incidental function of a hospital, supply-
ing human tissue is the fundamental and principal function of a
tissue bank. Procuring, processing, storing, and selling human
tissues are not incidental to the practice of tissue banking. The
court speaks to the fact that enterprises like tissue banking
should be encouraged, and that tissue banks "should not be re-
quired to bear the economic loss which might otherwise be im-
204 Cryolife, Inc v Superior Court, 110 Cal App 4th 1145 (Cal Ct App 2003).
205 Id at 1158.
206 In re Cryolife, Inc Securities Litigation, 2003 US Dist LEXIS 26170 (N D Ga 2003).
207 Cryolife, 110 Cal App 4th at 1157. It would seem that the purpose of the blood
shield law does not fit squarely with the legislature's intent regarding tissue banks.
208 Id at 1153.
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posed under the rules of strict liability which are applicable to
sellers of commercial products generally."
20 9
Second, the California Appellate Court misinterprets the
function and role of tissue banks. The court declared tissue
banks to be health dispensaries in the very way that hospitals
and clinics serve that role. The ruling suggests that tissue banks
are not commercial entities and that the items the companies
place in commerce are not commercial products.21 ° In this, how-
ever, the court possibly exaggerates the role and functions of tis-
sue banks (and ignores the privatization of hospitals too).211
Indeed, tissue banks are sophisticated entities, which func-
tion just as other corporations 212; they employ business strategies
to attract investors,21 a they attract the attention of financial ana-
lysts,214 and they have been investigated by the SEC.215 Unlike
hospitals, which serve patients, injured individuals do not call
the tissue banks for assistance or show up at their doors. Rather,
tissue banks do not work directly with consumers to serve their
immediate health needs. Instead, tissue banks are contacted for
what they sell, just as a maker of chairlifts, wheelchairs, and
walkers. Contrary to the Court of Appeals of California, the Ox-
ford Dictionary defines commercial as "making or intended to
make a profit; having profit rather than artistic or other value,
as a primary aim. "21 Commercial tissue banks are for-profit cor-
porations that offer stock traded on international stock ex-
changes, including our own in the United States. Tissue banks
certainly are not artistic organizations, even though increasingly
their commercial products are used for cosmetic purposes and
elective surgeries. Company business plans, sometimes posted on
209 Id at 1156 (quoting Hyland Therapeutics v Superior Court, 175 Cal App 3d 509,
516 (1985)).
210 Cryolife, 110 Cal App 4th at 1156.
211 See, for example, In re Cryolife, 2003 US Dist LEXIS 26170 (N D Ga 2003).
212 Consider id (plaintiff class of purchasers of Cryolife stock sued defendants, the
corporation and its principal officers, alleging that the corporation issued false and mis-
leading press releases and statements to artificially inflate the price of their stock).
213 Id. See also the Cryolife corporate website, available at <httpJ/www.cryolife.com/>
(last visited Jan 29, 2006) (describing Cryolife's corporate philosophy, services and quality
assurance measures).
214 See, for example, Aaron Smith, Tissue From Corpses In Strong Demand, CNN
Money (Oct 5, 2005) available at <http://money.cnn.com./2005/10/4/news/midcaps/al-
lograft> (last visited Feb 16, 2006) (discussing how companies in the allograft industry,
including Cryolife, obtain their materials and the volatility of their stock prices).
215 Paton, Cryolife Defendants Settle Claims, Rocky Mountain News B12 (Sept 16,
2005) (cited in note 177); Cryolife Inc. Agrees To $23 Million Settlement To End Share-
holder Suit, Securities Class Action Reporter at 8 (cited in note 178).
216 See The New OxfordAmezican Dictionary344 (Oxford University Press 2001).
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tissue bank websites, outline profit initiatives, investment
strategies, and describe key ways that investors can reap profits
from cadavers and body parts. Within the business sphere, tissue
banks compete unabashedly and project business-centered image
and such efforts have been quite successful.217
These factors, probably considered exogenous to the courts,
and therefore less relevant, actually help to illuminate the true
status and functions of tissue banks. Consider for example that
tissue banks reserve the right to contract with other businesses
about the body parts they acquire. Tissue banks can and do ex-
clude others from interfering with the tissues and body parts
they trade. If a company or individual attempted to interfere
with their collection of body parts, an enforceable remedy would
exist. By ignoring the role and function of tissue banks, courts
not only abrogate their responsibility to respond to the social,
legal, and cultural complications of contemporary biotechnology,
but also deny remedies to aggrieved patients.
On examination of the legal landscape, one realizes that in
this complicated, nuanced terrain the varied interests of biotech
companies too often outweigh the liberty interests of individuals,
including strongly held values of autonomy, the right to be free
from bodily intrusion, and the right to freely decide how one's
body will be used. In essence, courts ultimately favor the protec-
tion of the biotech research enterprise over the liberty interests
and even safety of the individual. In the battle between David
and Goliath, in the biotech context, Goliath almost always wins.
III. A NEW GENERATION OF LABELS
In Part III, I briefly explore the nuances of giving a particu-
lar legal status to the body; the pitfalls, challenges, and problems
of doing so. Courts have elucidated four possible conceptions of
the body and/or body parts and our relationship to it: property,
inalienable, possession, and service. This section addresses only
the potential status of the body as either a possession or prop-
erty.
Some commentators question the utility of "naming" the
body or conferring rights to individuals responsible for disposal
of remains. To them, the body and body parts represent a sacred
vessel that if re-characterized could lead to market concepts as-
sociated with human flesh and an eventual commodification of it.
217 Skloot, Taking the Least of You, The New York Times Mag 38 (April 16, 2006)
(cited in note 91).
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Accordingly, to these scholars, all market concepts in the body
are understood as bad.21 In a market paradigm, commentators
fear that individuals will desire to alienate their bodies or those
of their deceased relatives. The risk that some of these bodies if
commodified, according to Richard Titmuss, might place insalu-
brious tissues into the marketplace is quite high.219
Scholars warn that the poor and destitute will be drawn to
markets and when they are, sellers will engage in socially unde-
sirable behaviors, including stealing body parts. Commodifica-
tion of the body, according to anti-market bioethicists such as
Arthur Caplan, is akin to slavery-a paradigm to be avoided.
Beyond the unfounded fears of body part markets, ultimately the
necessity to ascribe legal status to the body remains. The legal
status we ascribe to the body will have great impact on tort,
property, and contract claims and potential plaintiffs' access to
the courts.
A. Body As Possession
Judges on the Ninth Circuit Court of Appeals recently tested
the thorny divide between theories of property versus possessory
interests in the body. In Newman v Sathyavagswaran,"° par-
ents of deceased children whose corneas were removed by the Los
Angeles County Coroner's office without notice or consent,
brought a Section 1983 action alleging a taking of their property
without due process of law. The complaint was dismissed by the
district court for a failure to state a claim upon which relief could
be granted. On review, the Ninth Circuit concluded that the
longstanding recognition in the law of California, paralleled by
national common law, that next of kin have the exclusive right to
possess the bodies of their deceased family members created a
property interest, the dispossession of which must be accorded
due process of law under the U.S. Constitution Fourteenth
Amendment.
Newman articulates a new conception of rights in the body
in the majority and dissent. In this way it represents a departure
from traditional formalism in body part jurisprudence. New-
man's majority recognizes a property interest in the right to de-
cide the disposition of a body. In contrast the dissent is far less
218 see Radin, 100 Harv L Rev at 1849 (cited in note 2).
219 See, for example, Richard M. Titmuss, The Gift Relationship: From Human Body
to Social Policy (New Press 1971).
220 287 F3d 786 (9th Cir 2002).
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generous, declaring that individuals only have the authority to
possess the body and that this interest is aesthetic at best. In-
deed, possessions of negligible magnitude confer upon the owners
or possessors the right to defend their interests in that thing.
That right to defend such an interest through civil remedy is far
from insignificant.
Judge Ferdinand Fernandez, in a passionate dissent, articu-
lated an alternative, new conception of the body as a possession
rather than property. In doing so, he rejected the majority's
analysis in Newman,221 which ascribed new value to the body by
interpreting a property right of parents to have been violated
when children's corneas were moved without consent and notice.
Fernandez attempted to move slightly beyond the stricter
formalism of the Eighth Circuit and various state courts in
Washington, Florida, and Georgia.222 Fernandez ultimately
reaches the same conclusion as his peers in other jurisdictions;
the body has no property status and therefore a conversion is not
an appropriate cause of action in relation to the body.223 How-
ever, the nuanced approach outlined by Fernandez is worthy of
note as a possible new judicial framework.
Like traditional formalists, judges adopting the possessory
interest framework will first look to the legislature for guid-
ance.2" Absent legislative enactments or agency regulations,
formalists will not seek to give new meaning to traditional
frameworks and perhaps for this reason, Fernandez's dissent
cannot clearly be situated within the conventional formalist
paradigm despite the fact that he rejects acknowledging property
interests or status in the body. Rather in the case of Newman,
Fernandez offers an alternative modern application of quasi
property theory, which is a slight, but important nuance in body
part jurisprudence. By doing so, he mildly betrays the formalist
convention that "the rule of law is about form."22 According to
the nascent theory of the body as "possession," duties are associ-
ated with individuals' relationship to the body, particularly dead
221 287 F3d 786, 800 (9th Cir 2002) (Fernandez dissenting).
222 See id (Judge Fernandez does not address whether a body merely is or is not prop-
erty with its associated rights, but rather what rights correspond with the state-imposed
duty to dispose of the body).
223 See id (declaring that states can, when conferring a duty to dispose of decedent's
body, limit property rights to mere possessory interests).
224 Id.
225 Antonin Scalia, Common-Law Courts in a Civil-Law System: The Role of United
States Federal Courts in Interpreting the Constitution and Laws, in A Matter of Inter-
pretation: Federal Courts and the Law3, 23-25 (Amy Guttman ed, Princeton 1997).
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bodies. Thus, if a right exists, it is a right only to possess the
body for purposes of burial and to destroy it.
226
Judge Fernandez rationalizes that "this so-called right is ac-
tually in the nature of a duty and expense designed to assure
that the remains will not simply be left about, but will be quickly
interred."27 He refers to this special set of responsibilities as
"something like a table of intestate succession for the purpose of
assuring that the right and duty land firmly on a defined
group."228 Fernandez describes this right as being grounded in
pragmatism, although he offers no further explanation. 29 Never-
theless, there are several common elements that follow this the-
ory, which was originally conceptualized as based on a "quasi
property interest."23 ° The core principles of quasi property inter-
ests include a concern for decency, consideration for others,
pragmatism, due haste, and entitlement to burial.
Specifically, this theory of body as possession is concerned
with decency for the dead and society. In sum, according to Fer-
nandez, our concerns should be focused simply on respect--or the
negative right to be free from the disrespectful treatment of oth-
ers. 231 Yet, Fernandez clearly articulates a division between the
law's concern for decent treatment of the dead and constitutional
protection. In other words, the duty to bury is not a constitution-
ally protected right of property. Because possession treats the
association with the body as a duty and burden on relatives, it is
less concerned about relatives and their desires except for how
they wish to bury or inter their deceased relatives. Thus, the
theory is not concerned with any value relatives or spouses may
extract from the body. It is an anticommodification position that
rejects the notion that the body should have any property-like or
commensurable status.
Fernandez's theory is not completely worked out, just as
there are limits in the traditional quasi property rights frame-
work. For example, the possession theory is also concerned with
timing, but its outcomes are somewhat arbitrary. Specifically,
possession theory confines one's possessory interests to the tim-
ing of death and burial. This narrow time stamping ignores con-
temporary medical, biotechnological, and social treatment of the
226 Newman, 287 F3d at 800 (Fernandez dissenting).
227 Id.
228 Id.
229 Id.
230 Pollard vPhelps, 193 SE 102, 106 (Ga Ct App 1937).
231 Newman, 287 F3d at 801 (Fernandez dissenting).
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body and its indeterminate state in cryopreservation, loans to
museums, medical schools and other institutions, and when it is
brain dead. In effect, the timing prong suggests that possessory
interests attach only for a short period at the immediate time of
death and not during life. Thus, an individual such as Moore
would not pursue a conversion claim under possession theory.
Moore's cells were extracted and exploited during life, not at
death.
Possessory rights are empty vessels. Proponents of this the-
ory might argue that there are no causes of action for which
courts may grant a remedy even in instances where the right to
possess is interfered with at death. In other words, interfering
with one's right to bury is a bad thing, but courts do not possess
the authority to grant a remedy. Also, the right to possess, ac-
cording to Fernandez, is not confined to the individual, but by
statute can also be bestowed upon the state.
In the Newman dissent, Fernandez declares that the state's
authority to extract tissues at death is not challengeable." 2 Thus,
an additional element to be worked out in this theory is how to
decide whether the state has the controlling interest at death or
the individual-irrespective of statute. As it stands, the outcome
of possessory rights according to this theory will differ from state
to state, offering no clear guidance for plaintiffs-even within the
same federal circuits. Fernandez might also conclude that ag-
grieved plaintiffs do not have any remedies that a court can pro-
vide except in distinguishing who can bury or donate organs.
B. Property
The Supreme Court has yet to address whether the rights of
control, possession, and privacy in one's body are property inter-
ests and thus "protected" by the Due Process Clause. Nor has it
addressed what Due Process protections are applicable to the
rights of next of kin to possess and control the bodies of their de-
ceased relatives.23 However, constitutionally protected property
rights extend "beyond actual ownership of real estate, chattels,
or money."2 34 Accordingly, these rights "are not created by the
Constitution ... they are created and their dimensions are de-
fined by existing rules or understandings."235 Like proponents of
232 Id.
233 Id at 789-90.
234 Id at 790 (quoting Board ofRegents vRoth, 408 US 564, 571-72 (1972)).
235 Newman, 287 F3d at 790 (quoting Board ofRegents, 408 US at 577).
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possession theory, property proponents find support for giving
the body legal status as property from the common law rules that
affirmed a quasi property right interest in the body.
Writing for the majority in Newman, Judge Raymond Fisher
cites an 1872 case to draw the parallel:
By the civil law of ancient Rome, the charge of burial was
first upon the person to whom it was delegated by the de-
ceased; second, upon the scripti haeredes (to whom the
property was given), and if none, then upon the haeredes
legitimi or cognate in order .... Their heirs might be com-
pelled to comply with the provisions of the will in regard
to burial. And the Pontifical College had the power of pro-
viding for the burial of those who had no place of burial in
their own right.236
Unlike Fernandez, Fisher and the majority in Newman de-
scribe rights and duties as being jural correlatives.237 At issue in
this examination is whether possession and control rise to the
level of a constitutionally protected interest. Property, for the
majority in Newman, is a "group of rights inhering in the citi-
zen's relation to the physical thing, as the right to possess, use
and dispose of it." 238 The court makes clear that to have a prop-
erty right or interest, one must have more than an abstract no-
tion of a thing, but rather, a "legitimate claim of entitlement to
it." 239 Concomitant with this idea is the protection found in laws
to shield one from interference with the thing said to be property.
The landscape however, is not clean here. Only the Ninth
and Sixth circuits have affirmatively offered that the body re-
mains property after choosing its burial.240 Professor Lori An-
drews cautions against being too swift in naming the body as
236 Pierce v Proprietors of Swan Point Cemetery, 10 RI 227, 235-36 (1872) (quoted in
Newman, 287 F 3d at 790).
237 Newman, 287 F3d at 790 n 5 (adopting Wesley Hohfeld's description of rights and
duties as "jural correlatives," which are described as "different aspects of the same legal
relation").
238 Id at 795 (quoting United States v General Motors Corp, 323 US 373, 378 (1945)).
239 Newman, 287 F3d at 795.
240 In defense of property, the courts articulate a distinction between property inter-
ests and an absolute right to commodify. Nor is the court convinced that simply because a
thing lacks economic value or is prohibited from sale, that it is not property. Newman,
287 F3d at 795; Brotherton, 923 F2d 477 (6th Cir 1991). Moore, 793 P2d at 501 (noting
that although Moore himself had no property interest in his cells, had "another medical
center or drug company ... stolen all of the cells ... from the UCLA Medical Center labora-
tory and had used them for its own benefit, there would be no question but that a cause of
action for conversion would properly lie against the thief").
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property, lest we fully comprehend the socioeconomic, cultural,
and political ramifications of such judicial or legislative interven-
tion.241 She wisely challenges us to think about the praxis and
pitfalls of granting property status to cells, organs, and conceiva-
bly all other parts that have recently been subject to market
forces, including brains, bones, and limbs. To the extent that
property rights are recognized in body parts, plaintiffs may have
greater access to courts because they will actually have justicia-
ble claims. On the other hand, it is true that alternative forms of
negation and possible payment might arise, including joint ven-
tures between patients and their physicians. It is also conceiv-
able that individuals might desire to invest in the products de-
rived from their bodies.
Property proponents, such as the majorities in Newman,
Brotherton, and Martin, argue that "the right of every individual
to the possession and control of his own person, free from all re-
straint or interference of others" is a well established principle,
recognized by the US Supreme Court.242 This right, according to
the majority, is deeply rooted in the conscience, traditions, and
culture of Americans.243 It is "to be ranked as one of the funda-
mental liberties protected by the 'substantive' component of the
Due Process Clause."2" Quoting Schmerber v California', the
Newman court asserted that "the integrity of an individual's per-
son is a cherished value of our society."246
Accordingly, property proponents, just as the "body as pos-
session" scholars, are concerned with human dignity. Property
proponents argue that the physical invasion of the body is offen-
sive to human dignity. They extend the notion of property inter-
est to the decisions that affect end-of-life decisionmaking. They
evoke the right to die cases, starting with Cruzan v Missour 4 7 ,
to draw parallels with the contemporary biotech cases, and par-
ticularly the compelled donation/presumed consent laws. For ex-
241 See Lori Andrews and Dorothy Nelkin, Body Bazaar: The Market for Human Tis-
sue In The Biotechnology Age (Crown 2001) (warning of an inevitable devaluation of
human life resulting from business interests in harvesting human tissues).
242 Newman, 287 F3d at 789; see also Brotherton, 923 F2d at 481 (extending rights in
oneself to "quasi-property" rights in decedent's next of kin); Martin v Young Kim, 2005
US Dist LEXIS 20595 (ND Ind 2005) (applying Brotherton reasoning to a refusal to allow
a kidney transplant from decedent to decedent's cousin due to a mandatory autopsy law
for homicide victims).
243 Newman, 287 F3d at 789.
244 Id.
245 384 US 757 (1966).
246 Newman, 287 F3d at 789 (quoting Schmerber v California, 384 US at 772).
247 Cruzan v Missouri Dept of Health, 497 US 261 (1990).
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ample, in Cruzan, the court expressed the view that a right to die
with dignity emanates from "the right to determine what shall be
done with one's own body [which] is deeply rooted in this Na-
tion's traditions ... and is securely grounded in the earliest com-
mon law."24
Finally, property rights are not absolute and it would be
problematic to interpret them as so. For any number of public
policy reasons, "the law limits or even forbids the exercise of cer-
tain rights over certain forms of property." 9 For example, own-
ers of property can be restricted from using their land in any
manner they desire. Moreover, foods, cosmetics, drugs, alcoholic
beverages, firearms, explosive materials, and other property are
subject to the public health and safety laws of any given commu-
nity.25 ° Even with such limitations however, we learn that prop-
erty rights can coexist with regulatory norms that limit their
reach.
IV. LIBERTY INTERESTS AND REMEDIES
Part IV of this Article studies the applicability of traditional
tort remedies for biotechnology breaches involving the body. Part
IV.A examines the application of strict liability to claims against
human tissue manufacturers for breach of duty. Part IV.B ana-
lyzes whether takings theory applies to cases of presumed con-
sent and nonconsensual takings by government agents.
Tort law is a creature of the common law. The inherent abil-
ity of the common law to grow, change, and adapt to the social
demands of the communities it serves is its "most significant fea-
ture."25' Thus, whatever remedies are found for plaintiffs in body-
tort disputes are predicated on courts moving away from a for-
malist approach to body part adjudication to one that is more
consistent with the contemporary ways in which the body is used
in technology. As society advances, so must the law adapt and
change to respond to inventions, trade, commerce, and biotech-
nology.
Adopting either of the approaches offered here will require
an expansion in the common law and the application of tort theo-
ries in ways not envisioned centuries or even decades prior. But
248 497 US at 305(Brennan dissenting).
249 Moore, 793 P2d at 509 (Mosk dissenting).
250 Id at 509-10.
251 See id at 507 (Mosk dissenting) (arguing that the Supreme Court does not need to
look to the legislature to establish a claim for conversion in Moore's case).
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there are sound social policy reasons for expanding the law to
address citizen complaints. As Justice Mosk iterates in his dis-
sent in Moore, "[i]n our contemporary complex industrialized so-
ciety, advances in science and technology create fungible goods
which may harm consumers .... The response of the courts can
be either to adhere rigidly to prior doctrine, denying recovery to
those injured by such products, or to fashion remedies to meet
these changing needs."252
A. Product Liability
Most surgeries involving the use of cadaver tissues are elec-
tive; the surgeries enhance the quality of life after strain or ten-
sions in the knees or other body parts.25 Soft tissues used for
heart valves, on the other hand, are life-saving products, trans-
planted into patients with life-threatening conditions." Most
patients who elect to use life-enhancing or life-saving therapies
may be unaware of the "brands" or manufacturers of the tissues
used in these routine operations. More people successfully sur-
vive implantation surgeries than die or become paralyzed. On
the other hand, some illnesses will not be detected as quickly as
in the stories described in Part I.
Section A visits the stories of several individuals who suf-
fered from fatal or near fatal diseases after implantation of in-
fected human tissue. As a market share, they are a very small
group. Weeks, sometimes months later, the bacteria may be dis-
covered and its link to the implantation may be overlooked. In
addition, patients and their physicians may not attribute the
postoperative diseases to the cadaveric implanted parts; most
might assume that only tested tissues would end up in the
stream of commerce and they would be wrong.
The first question to consider is if allegations such as those
put forth in Model C (Cryolife v Superior Court) can be estab-
lished as true, whether product liability can attach for mislead-
ing the public and placing faulty products in the marketplace.
Three main theories provide plaintiff relief for product-related
252 Id (Mosk dissenting) (citing Sindell v Abbott Laboratories, 26 Cal 3d 588 (1980)).
253 Blakeslee, Recall is Ordered at Large Supplier of Transplant Tissue, NY Times Al
(Aug 15, 2002) (cited in note 90); Jill Burcum and Josephine Marcotty, '01 Death Leads to
a Recall of Tissue, Minneapolis Star Tribune 1A (Aug 15, 2002) (noting that "[s]urgery
that relies on the cadaver tissue is mostly elective, meaning people can postpone or cancel
it").
254 See Ginny Merriam, Despite Recalls, Doctors Still Use Heart Technique, The Mis-
soulian B1 (Sept 11, 2002).
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injuries: negligence, breach of warranty, and strict liability.
Strict liability provides a more substantive remedy for plaintiffs
than traditional negligence law because damages are not limited
to pure economic loss. For this reason, corporations are more in-
clined to view product liability as a purely punitive remedy for
injured plaintiffs. In most states, to prove a strict liability claim
the plaintiff must demonstrate proof of an injury, but she is not
required to show a lack of due care by the defendant.
Greenman v Yuba Power Products,255 another California
case, is the landmark decision for modern product liability
claims. In Greenman, the Supreme Court of California consid-
ered whether the retailer and the manufacturer of a Shopsmith,
a power tool "that could be used as a saw, drill, and wood lathe,"
could be held liable for head injuries sustained by the plaintiff
when an attachment advertised and sold for the tool unexpect-
edly flew out of the machine and struck Mr. Greenman on the
forehead.
According to Justice Traynor in the Greenman decision, a
manufacturer is strictly liable in tort "when an article he places
on the market, knowing that it is to be used without inspection
for defects, proves" to be defective and causes an injury to "a hu-
man being."25 The purpose of strict liability is to insure that the
costs of injuries resulting from defective products are borne on
manufacturers that place goods in the marketplace rather than
the powerless individuals who purchase the products and are
otherwise unable to protect themselves. Traynor suggested that
implicit in products being on the market is the representation by
its manufacturer that "it would safely do the jobs for which it
was built."27
The Restatement (Second) of Torts provides the general
framework adopted by most states. Section 402 A of the Re-
statement establishes the test for strict liability for the manufac-
ture or distribution of defective products. It provides:
(1) One who sells any product in a defective condition un-
reasonably dangerous to the user or consumer or to his
property is subject to liability for physical harm thereby
caused to the ultimate user or consumer, or to his prop-
erty, if
255 Greenman v Yuba Power Products, Inc, 377 P2d 897 (Cal 1963).
256 Id at 898.
257 Id at 901.
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(a) the seller is engaged in the business of selling such
a product, and
(b) it is expected to and does reach the user or con-
sumer without substantial change in the condition in
which it is sold.
(2) The rule stated in Subsection (1) applies although
(a) the seller has exercised all possible care in the
preparation and sale of his product, and
(b) the user or consumer has not bought the product
from or entered into any contractual relation with the
seller.258
Thus, product liability claims require only that the plaintiff,
the injured party, demonstrate that the product is defective. The
plaintiff is not required to show privity between the plaintiff and
manufacturer. Neither is the plaintiff required to demonstrate
that the manufacturer acted "unreasonably." Strict liability has
been interpreted to be a "pro-plaintiff" theory of law because of
its less rigid requirements to establish manufacturer liability. 259
Part of the rationale for this is that manufacturers are in the
better position to prevent the accidents that result from their
defective products.26 °
Plaintiffs assume that advertisements about the safety and
utility of the manufacturer's products are true and that the pur-
chased products are free from defects. The defects covered under
strict liability law can be (a) manufacturing defects (products
that fail to meet the manufacturers' specifications); (b) design
defects (products with unsafe designs); and (c) defects in warn-
ings or instructions or products that lack information to make
258 Restatement (Second) of Torts, § 402(a) (American Law Institute Publishers 1965).
259 See David G. Owen, The Puzzle of Comment J, 55 Hastings LJ 1377, 1377 (2004)
(noting that "section 402A ... generated the expansive, plaintiff-friendly doctrine of strict
liability in tort for the sale of products that are defective in any of three fundamentally
different ways-in manufacturing, warnings, or design").
260 Product manufacturers are almost always in a better position to prevent harm
caused by defective products. See Suzanne Ernst Drummond, Des and Market Share
Liability in Ohio-A Lesson in How What You Don't Know Can Hurt, 67 U Cin L Rev
1331, 1344 n 112 (1999) ("'(1) [T]he manufacturer should bear the cost of injury as be-
tween it and an innocent plaintiff, (2) manufacturers are better able to bear the cost of
injury resulting from defective products, and (3) because manufacturers are in a better
position to discover and prevent product defects and to warn consumers of harmful ef-
fects, imposing liability would further ensure product safety.'") (quoting Sindell v Abbott
Laboratories, 607 P2d 924, 936 (Cal 1980)).
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their use less dangerous.26' That such defects are covered under
the scope of strict liability law can be explained by the need to
protect an otherwise vulnerable public from injurious conditions
caused by manufacturers.
The public policy rationale for product liability was estab-
lished by Traynor's concurring opinion in the infamous Escola v
Coca-Cola Bottling Co of Fresn262 case where he suggested that
fairness in a modern, industrialized society requires making
manufacturers responsible for the injuries caused by their prod-
ucts. 263 In that case, a waitress was injured by an exploding
Coca-Cola bottle.2" Although the court affirmed the judgment
against the manufacturer based on another tort doctrine,
Traynor's concurring opinion opened the door for strict liability
consideration.265
To determine whether strict liability should apply to tissue
manufacturers, we must consider whether their activities fall
within the general framework established through the Restate-
ment and prior case law, which involves non-tissue manufactur-
ers. The primary prong for successfully establishing a product
liability claim against a manufacturer is to demonstrate that the
product was defective.266 However, the defendant class is not lim-
ited to the manufacturer of products. Rather any entity that
plays a role in the manufacture, distribution, or sale of a product
is a potential defendant and therefore subject to liability.267
261 See Owen, 55 Hastings IJ at 1377 (cited in note 259).
262 Escola v Coca-Cola Bottling Co ofFresno, 150 P2d 436 (Cal 1944).
263 Id at 440-41 (Traynor concurring).
264 Id at 437.
265 Jimenez v Superior Court, 58 P3d 450, 452 (Cal 2002); Murphy v E R Squibb and
Sons, Inc, 710 P2d 247, 258 (Cal 1985); Trust vArden Farms Co, 324 P2d 583, 584 (Cal
1958); Zentz v Coca Cola Bottling Co of Fresno, 247 P2d 344, 347 (Cal 1952); Gordon v
Aztec Brewing Co, 203 P2d 522, 524 (Cal 1949).
266 Brady L. Montalbano, Comment, It's Not Easy Being Green, 14 Penn St Envir L
Rev 111, 121-22 (2005) ("[T]he second element necessary to sustain a strict products
liability cause of action is that the product must contain a defect. Under the Restatement
(Second) of Torts § 402A, there are currently three types of recognized product defects:
manufacturing defect, failure to warn (inadequate warning of defect), and design de-
fect.").
267 Richard C. Ausness, Tell Me What You Eat, And I Will Tell You Whom to Sue, 39
Ga L Rev 839, 876-77 (2005)
[T]hose who place finished products into the stream of commerce may be held
liable for any defects in their products and may also have a duty to warn users
or consumers about any inherent risks associated with their products. The new
Restatement of Torts, however, acknowledges that suppliers of raw materials
and component parts should not be held liable for injuries caused by defective
finished products when the materials they supply are not themselves defective.
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Within this framework, when a product does not function in a
way in which its manufacturers intend, and the defect contrib-
utes to an injury suffered by the plaintiff, the product is charac-
terized as having a manufacturing defect.2 68 Moreover, if a prod-
uct has a manufacturing or design defect, plaintiff can recover
under strict liability for injuries related to those defects regard-
less of manufacturer warning labels being present.2 69
Liability in the tissue industry for the distribution, process-
ing, handling, and selling of products is largely premised on
whether we consider those processes to be the manufacturing
and processing of a "product" or providing a "service." Such is-
sues in the nomenclature may best be resolved by turning to the
dictionary for a better grasp of our social understanding of a
product versus a service. According to the American Heritage
Dictionary, a product is "something produced by human or me-
chanical effort or by a natural process."27 ° A service, on the other
hand, is defined as "employment in duties or work for an-
other."27' The dictionary compares a service with providing con-
sultation or doing a favor for an individual.
Thus, when compared to a "service" or "product," human tis-
sues much more closely resemble a product. Human tissue is in
fact something produced biologically, and arguably by human
effort, which is a natural process. Often, the tissue is further
processed by tissue banks and sometimes entirely reconstituted.
Human tissues are tangible, biological materials that exist not in
an ethereal state, but in real life. Medicines and other technolo-
gies derived and produced from human tissues are considered
products. Yet, we must consider the question of defect and
whether the manufacturer's having control over the tissues
meets the requirements established by the Restatement and
prior case law. To help us determine whether Cryolife's human
tissue product was actually defective, we should turn to the prior
health status of the patient and his postoperative condition.
While it is true that patients could acquire diseases in hospitals,
268 See Owen, 55 Hastings IJ at 1378-79 (cited in note 259) (describing the three
forms of product defects: "(1) manufacturing flaws-unintended physical irregularities
that occur during the production process; (2) design inadequacies-hazards lurking in a
product's engineering or scientific conception that may reasonably be avoided by a differ-
ent design or formula; and (3) insufficient warnings of danger and instructions on safe
use-the absence of information needed by users to avoid product hazards").
269 See id.
270 American Heritage Dictionary at 1399 (American Heritage 4th ed 2000).
271 Id at 1591.
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it is far more direct and proximate that contaminated implants
will result in life-threatening illnesses.
Consider the case of Brian Lykins; the deadly bacterium
found in his implanted knee tendon, Clostridium sordelli, was
not pre-operatively present in his body.272 Yet, following Lykin's
death and illnesses in several other patients that resulted from
similar implants in Minnesota from Cryolife products, the FDA
visited the manufacturer.273 In a subsequent report, the FDA
emphasized the unusual length of time the cadaver, which would
become the tendon "supplier," remained unrefrigerated prior to
271processing. It was clear that nineteen hours without refrigera-
tion was well outside the tissue industry norm.275 Cryolife's
claims that its products were safe and that the rare bacterium
could have been picked up anywhere were less persuasive when
CDC investigators found "tissue from the donor's other knee,
which had not been implanted in anyone, tested positive for Clos-
tridium sordelli."276 Moreover, of the nearly twenty tissue sam-
ples that were not implanted, at least two contained the exact
bacteria that killed Lykins.2" Scientists from the CDC linked all
Clostridium infected tissues to the bacteria in the cadaver's gas-
trointestinal tract.278
If human tissues are more likely products than services,
then their contamination would presumptively make them "un-
safe" products. Moreover, an unsafe product used for medical
272 See Sandra Blakeslee, Lack of Oversight in Tissue Donation Raising Concerns, NY
Times 11 (Jan 20, 2002) (cited in note 83) (indicating that tissue from the donor tested
positive for the deadly bacteria).
273 Burcum and Marcotty, '01 Death Leads to a Recall of Yissue, Minneapolis Star
Tribune 1A (Aug 15, 2002) (cited in note 253) (describing a two-week inspection of Cryo-
life headquarters by FDA inspectors: the "testing methods ... to detect bacterial and other
types of contamination were deficient and not reliable").
274 Centers for Disease Control, Update, Allogragt-Associated Bacterial Infections-
United States, 2002, Morbidity and Mortality Weekly Report Vol 51(10) 207-210 (Mar 15,
2002), available at <http'//www.cdc.gov/mmwr/PDF/wk/mm5llO.pdf> (last visited Apr 14,
2006) (indicating that the delay in refrigeration of the donor contributed to the bacterial
contamination).
275 See, for example, In re Cryolife Securities Litigation, 2003 US Dist LEXIS 26170,
*8 (2003) ("Cryolife procures cadavers that do not meet the standards of other tissue
processors. Notably, other processors do not accept cadavers that have not been refriger-
ated within twelve hours of death, because the decomposition of a non-refrigerated ca-
daver releases microorganisms that contaminate the cadaver.").
276 See Blakeslee, Recall is Ordered at Large Supplier of Transplant Tissue, NY Times
Al (Aug 15, 2002) (cited in note 90).
277 Id. See also Centers for Disease Control, Morbidity and Mortality Weekly Report
Vol 51(10) 207-210 (Mar 15, 2002) (cited in note 274) (noting that of the "19 nonimplanted
tissues" from the donor, the bacteria was identified in two samples").
278 Centers for Disease Control, Morbidity and Mortality Weekly Report Vol 51(10)
207-210 (Mar 15, 2002) (cited in note 274).
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processes would seem to be inconsistent with manufacturer in-
tent, and certainly inconsistent with patient, physician, and hos-
pital expectation. Unsafe products by their very definition are
defective. Likewise, infection of deadly viruses in transplantable
tissue must render the tissues defective products. According to
the common law and Restatement of Torts, a manufacturer need
not know nor intend to distribute a defective product in order for
strict liability to attach." 9 Rather, it is sufficient that the item
appear in the stream of commerce and a human being is injured
by the product.280 Recovery in strict liability is allowed if those
elements are met-and they are in these cases.281
Finally, although it would seem unwise to view organs as
services, doing so invites an alternative analysis far different
from the Appellate Court in Cryolife v Superior Court. Cryolife's
argument that a body part is a service might be more persuasive
were the company selling kidneys rather than cadaver tissues
exactly because kidneys are life-saving treatments, not elective
or cosmetic surgeries. Thus, unlike with tissues, we might view
the kidney as a product, and yet provide immunity from liability
for entities that assist in providing them (much as we do now).
As much as a kidney is tangible, are hospitals selling "products"
or providing "services" when transplants are made available to
patients like Brian Lykins? Hospitals provide a service in trans-
planting organs within a thin time frame and narrow chain of
command to do so. Hospitals and surgeons (even if they might
desire to do so) cannot legally purchase, nor stockpile, organs for
transplantation; the supply is far too limited and organs in-
tended for transplantation expire far more quickly than human
tissue. Thus, the technology is unavailable should there even be
interest in such an industry. The storage life of a kidney is hours,
but for tissues it can be years after processing.
Analogies drawn between organs and tissues and the indus-
tries that "handle" them are overstated. The two are vastly dif-
ferent and the "controllers" far differently motivated. Surgeons
and hospitals lack the ownership interests in the organs they
transplant as it also seems with regard to the prospective recipi-
ent. Yet, tissue banks have a proprietary and legally recognized
interest in their tissue products. The companies' rights to litigate
279 James A. Henderson, Jr. and Aaron D. Twerski, Intent and Recklessness in Tort:
The Practical Craft of Restating Law, 54 Vand L Rev 1133, 1137 (2001) (explaining that
intent, which implicates moral culpability, is not present in strict liability).
280 See id.
281 See id.
THE UNIVERSITY OF CHICAGO LEGAL FORUM
for the misuse, misappropriation, mischaracterization, and theft
of the tissue are all legally protected. Even with an understand-
ing that hospitals provide a service and not a product, consider
that the common law has evolved to allow tort claims to proceed
against hospitals for negligent actions involving organ transplan-
tation.
Lastly, any tissue-related services that existed in 1968, the
year of the Uniform Anatomical Gift Act's ("UAGA") enactment,
were on the whole far less pecuniary, and focused on research.2 2
The nature of the industry that seeks protective status through
the UAGA, and immunity through blood shield regulations does
not appear to be the "model" intended for protection from public
accountability and scrutiny.
Strict liability is an appropriate remedy for patients injured
by tissue banks placing contaminated products in the stream of
commerce. Application of strict liability to tissue bank manufac-
turers based on their strictly pecuniary interests comports with a
traditional doctrinal approach in this area. Consider the public's
inability to test tissue banks' products prior to purchase and im-
plantation. Strict liability as a legal remedy in cases where such
egregious breaches in companies' duties seems consistent with
contemporary social notions of fairness and justice.
Ultimately, tissue banks operate in a risk-intense industry
and are in the best position to avoid accidents. Thinking other-
wise exempts tissue banks from the type of liability to which sis-
ter industries are exposed, such as intra uterine device manufac-
turers, makers and sellers of tools, and car manufacturers. It is
well established through the Beshada v Johns-Man vile Products
CorpY83 line of cases that courts will impose responsibility on a
defendant for its failure to warn about risks that were scientifi-
cally unknowable at the time the defendant marketed its prod-
uct.2" 4 Torts are about social policy-social insurance to be ex-
act-and this being so, public policy rightfully fixes the burden of
placing healthy, non-diseased human tissues on the tissue banks
that collect, process, and sell these products. To place the burden
of policing the industry on the consumer, without providing a
282 Alicia M. Markmann, Comment, Organ Donation: Increasing Donations while
Honoring Our Longstanding Values, 24 Temple J Sci Tech and Envir L 499, 504-05
(2005) (explaining the altruistic roots of the UAGA).
283 447 A2d 539 (1982).
284 See, for example, In re Asbestos Litigation Venued in Middlesex County, 491 A2d
700 (NJ 1984); Michaiko v Cooke Color and Chemical Corp, 451 A2d 179 (NJ 1982);
Leonen v Johns-Manviile Corp, 717 FSupp 272 (D NJ 1989); Campolongo v Celotex Corp.,
681 FSupp 261 (D NJ 1988).
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remedy for the injured consumer, ignores the purposeful civil
check on markets.
B. Takings Claims
Engaging takings law in the sphere of body parts negotia-
tions when A is deprived by B (as well as the collective) is a
natural evolution in the law itself. Inherently, there is something
troubling and plain wrong when B takes from A without provid-
ing compensation-whether B is a private individual or the state.
The problem beyond the obvious invasion and the emotions that
attend such an action, include A bearing the transaction costs of
the deprivation, exposure to E,F, and G to do the same (if there
are no disincentives or penalties), and the loss of the thing itself.
In the medical and biotech contexts, B might argue that A is in a
pareto superior position if what was taken happened to be ab-
normal or even diseased. Because people tend to attach values to
those dichotomous positions; A with an abnormal tumor is in a
bad condition, if B takes the tumor and keeps it, A is better off-
particularly if she happens to be poor and cannot afford surgery.
But such logic although seductive, is deceptive, incomplete, and
wrong. If A's capacity to contract and ability negotiate with C or
D to develop the unique cell line found in her tumor is denied, a
taking far more valuable than tissue and flesh has occurred.
Rights to contract have been undermined, rights in the thing it-
self and its future potential, and the most basic right of auton-
omy-to be free from the interference of others are implicated by
B's actions. Future cases will bear this out, and they will oblige
us to rethink Moore.
The Newman and Brotherton cases will likely be instructive
on whether future courts are willing to conceptualize tissues or
the rights to them as property and thus provide a remedy under
takings theory. Both cases involved the nonconsensual removal
of corneas from cadavers and were initiated by relatives whose
exclusive rights to burial had been interrupted by the state.
Plaintiffs might be more inclined to pursue a takings remedy as
they are not limited to one legal theory when bringing suit for
such an action. In Dico, Inc v United States,"5 for example, the
plaintiff claimed relief under both due process and takings the-
ory. The court noted that the fact that the legal theories pre-
285 48 F3d 1199 (Fed Cir 1995).
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sented by the plaintiff are different does not require that the re-
lief be different.286
In Newman, a presumed consent case, the Ninth Circuit rec-
ognized a property interest in a dead body. In articulating an
analysis for the majority, Judge Fisher invoked the Fourteenth
Amendment, noting that it prohibits states from "depriving any
person of life, liberty, or property without due process of law. "287
The threshold for a case alleging a state deprivation is that a
plaintiff must show: 1) a deprivation; 2) of property; 3) under
color of state law. If plaintiffs are able to prove those three ele-
ments, as indicated in a 48 USC section 1983 claim, the court
must consider "whether the state afforded constitutionally ade-
quate process for the deprivation."2
8
How might takings theory actually apply? A property owner
cannot bring a claim for just compensation until she has "sought
and been denied compensation through procedures provided for
this purpose."2 9 If the plaintiff presents a facial challenge to the
regulation, no exhaustion of remedies is required. Typically,
however, if the plaintiff is challenging the regulation as it applies
to a particular property, the plaintiff must exhaust all remedies
provided by the government. Herein lies a problem for unwitting
presumed consent participants. Actual opportunities to object
and be heard are more illusory than real. States have not estab-
lished "opt-out" agencies or government entities where individu-
als can refuse to participate in a presumed consent scheme. No-
tice prior to harvesting is not required, but advised. Nor is there
a hearing or adjudication mechanism prior to the tissue extrac-
tion.
We can also consider takings in the context of Moore. In re-
cent years, scholars and commentators have pondered whether
Moore's cells became valuable only after they were no longer a
part of his body. Such questions are sensitive to the investment
of time, resources, and research invested by Dr. Golde in develop-
ing the cell line; yet these questions tend to overlook that it was
a cell line developed from a spleen and fluids that were not his or
the Regents of the University of California to "take." It is worth
scrutinizing this model detached from the more arcane (and
false) notion of the body as having no intrinsic value. What if, as
286 Id at 1203.
287 Newman, 287 F3d at 788.
288 Id at 789.
289 27 Am Jur 2d Eminent Domain § 416 (2005).
382 [2006:
317] FORMALISMAND THE LEGAL STATUS OFBODYPARTS 383
in Model A(2), the goods coerced from Moore were unrefined
diamonds, rather than the more valuable spleen and cell line?
Would the only calculable injury have been Y's (the lawyer's)
breach of fiduciary duty-the failure to disclose that he had a
financial interest in the diamonds?
As discussed earlier, property rights are not absolute, mean-
ing that they are not absolutely free from governmental interfer-
ence. However, the governmental unit initiating the taking must
abide by constitutional principles, and thus cannot interfere with
property without providing notice and an opportunity for owners
or possessors of property to contest the action.29" Nor is the gov-
ernment's authority to take what it pleases, even for a noble pub-
lic use, uncontested or absolute. Takings may also be effectuated
differently depending on which arm of the government seeks use
of the thing. For example, state and local government accession
for public use can be effectuated by public referendum, the vote
of an administrative board, and arguably a local administrative
body with health and welfare oversight. At the federal level, the
State can impose on a property right through legislation and by
establishing a special procedure for ascertaining compensation.291
Deprivations that warrant just compensation because a gov-
ernment actor is involved implicate the Fourteenth Amendment.
The Fourteenth Amendment prohibits states from depriving any
person of life, liberty or property without due process of law. The
property interests protected by procedural due process extend
well beyond actual ownership of real estate, chattels, or money.
The procedural protections of property under the Fourteenth
Amendment are a safeguard of the security interests that each
citizen has acquired.
Recent case law demonstrates the complex and sometimes
inconsistent application of takings protections,292 but neverthe-
less, the rationale for the takings clause is to prevent an unjust
deprivation or imposition of costs on a few that "should be borne
by the public as a whole."293 It would logically follow, then, that a
government appropriation of private property (human tissue) for
290 Note however, these constitutional guarantees are also not absolute. For example,
the state must not always provide a property owner a right to a hearing to determine the
necessity of a particular taking if the taking is for a public use. Id.
291 Id.
292 See, for example, Kelo v City of New London, 545 US 965 (2005) (holding that the
city's taking of private property to sell for private development qualified as "public use"
within the meaning of the takings clause).
293 Armstrong v United States, 364 US 40, 49 (1960).
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a public good (transplantation) must be conditioned on just com-
pensation. Presumed consent laws, passed in more than twenty-
five states, and actively used in nine, raise the relevance of
whether takings theory is applicable to government interference
with the human body for purposes of furthering biotechnology
and the public good. To be sure, the takings clause does not pro-
hibit the state from interfering with one's body, but it requires
that the government "assert its interest and subject them to
scrutiny when it invades the rights of its subjects."294
Pennsylvania Coal Company v Mahon2 95 established that a
regulation can constitute a taking under the Fifth Amend-
ment.2 96 According to the court, "while property may be regulated
to a certain extent, if a regulation goes too far it will be recog-
nized as a taking."297 The issue whether a taking has occurred
will turn on whether the regulation or statute has penetrated the
sacred boundaries of space, be it land, air, or in this case the
body, and thus require just compensation. The Pennsylvania
Coal court identified at least one important factor in determining
when the provision has gone too far and must be considered a
taking-the degree of diminution in value of the thing itself.298
Other courts have further extended this line of reasoning to es-
tablish additional factors in determining whether a taking re-
quiring just compensation has occurred. Some of the factors con-
sidered include: the economic effect on the individual deprived,
the degree of interference with reasonable investment backed
expectations, and the nature of the government action.299
Takings are not determined by the volume or amount of a
"thing" which has been appropriated. Even if the property is a
minuscule representation of the entirety, a successful takings
action may be sustained. 0 In a surgical context, an appropria-
tion of a cornea is as substantial as the severing of an arm or leg.
When a medical examiner or coroner harvests corneal tissue
from a cadaver's eyes and implants the material into another, it
294 Newman, 287 F3d at 799.
295 260 US 393 (1922).
296 Id at 415.
297 Id.
298 Id.
299 Pennsylvania Coal Company, 260 US at 415 (discussing the diminution in value of
the property); Agins v City of Tiburon, 447 US 255 (1980) (discussing the complete loss of
economic value of the property).
300 Loretto v Teleprompter Manhattan CATV Corp, 458 US 419 (1982) (defining the
installation of a small cable box on landlord's residential apartment building as a taking,
regardless of the fact that the physical invasion of the landlord's property was not large).
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is apparent that an invasion has occurred. An analogous illustra-
tion is the government appropriating a narrow strip of land in
the middle of an owner's property for purposes of building a road.
The size of the road is not the determinate factor; one must con-
sider only the fact that land has been excised for public benefit.
Assuming that property rights have vested in the next-of-kin,
that individual may successfully argue that nonconsensual cor-
nea or heart valve removal from a cadaver is an invasion.
The public use prong of the takings clause requires that the
state have a clear public interest in improving the health and
well being of its citizens. One could quite easily reach the conclu-
sion then, despite the fact that we as a society abjure the rescue
doctrine, that providing sight for the blind and hearing for the
deaf would be a legitimate government objective, resulting in a
benefit for members of the public. However, tissue extractions
without notice and an opportunity to appeal violate constitu-
tional norms, particularly for such an intimate deprivation. 1
Thus, appropriating human biological materials from cadavers to
benefit members of the public can be construed as a public use of
private property.
Perhaps most challenging in parsing out whether takings
theory has any application to the human body involves applica-
tion of the just compensation element. The final prong of the tak-
ings analysis requires establishing just compensation. Just com-
pensation for a government taking of human biological tissue is
difficult. Unlike skin, ova, blood, and sperm, which are controlled
to some extent by market and social forces, corneas, heart valves,
and organs are banned from commercialization. Thus, determin-
ing the best way to assess compensation poses a challenge, but
should not defeat a justiciable claim. Of the methods available to
gauge just compensation, at least three seem viable. First, one
can directly ascertain the market value applied by tissue banks
and such companies to purchasers. In other words, we might look
to prices established by the industry itself. Such data should not
be difficult to obtain. Unlike at the time of Moore, such costs are
now well established. Second, conversion usually applies to
situations where the fair market may not be able to establish a
standard value. Establishing just compensation through this
method is more speculative than using market value, but might
301 Prior work discusses the racial and class implications of such policies, including
issues addressing distributive justice and thus these issues will not be discussed here.
See Goodwin, Black Markets: The Supply and Demand of Body Parts at 17 (cited in note
57).
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be seen as an option by courts. Third, compensation might be
based at the same level recoverable in a suit for wrongful inter-
ference with a corpse. °2
Indisputably, states have an interest in aiding its citizens.
Sometimes that interest might involve calling upon and burden-
ing the collective to enhance the medical benefits of the individ-
ual or whole. Yet the nuances that shape those obligations are
difficult to unpackage and are increasingly challenging as bio-
technology provides a means to solve so many of our health prob-
lems. Nevertheless, the US Constitution "requires the govern-
ment to assert its interests -and subject them to scrutiny when it
invades the rights of its subjects." °3 In this new world of bio-
technology, citizens deprived of rights to their relatives' bodies,
or defrauded by government actors in extraction of body parts,
must be allowed the opportunity to fully pursue such claims.
Their interests must be protected against the tyranny of biotech-
nology and blindness of the legislature.
CONCLUSION
Why does the legal status of body parts really matter? We
could simply adopt a system whereby the burden of risk is placed
upon patients, relatives, and buyers. Yet placing the onus on citi-
zens to combat the excesses of biotechnology would be unfair and
contrary to the best ideals of justice and sound public policy. Nei-
ther does such a proposition seem realistic. The challenge then, it
seems, has much to do with how judges will judge.
Annually, over one million Americans undergo surgeries in-
volving soft-tissues, skin, bones, and tendons acquired from ca-
davers."°4 Human tissue and organs suitable for burial at death
or disposed of after medical procedures are given new life and
302 See Erik S. Jaffe, Note, Nonconsensual Organ Removal, 90 Colum L Rev 528, 572
n 214 (1990) (noting that items with no market value are often converted based on subjec-
tive value rather than awarding a nominal amount).
303 Newman, 287 F3d at 799.
304 In the past few years the number of Americans utilizing human allografts has
nearly doubled. Andrew Bridges, Feds Close Body Parts Harvesting Company, Associated
Press (August 19, 2006) ("More than 1.3 million Americans each year have operations or
procedures that use bone, skin, corneas or other types of tissue from donated cadavers.
These range from dental implants using ground bone to knee ligament and spine re-
pairs."). Schapiro, Banking on the Gift of Yissue, Milwaukee Journal Sentinel G1, (May 2,
2005) (cited in note 92). See also, Department of Heath and Human Services, Office of
Inspector General, Oversight of Tissue Banking (Jan 2001), available at
<http://www.fda.gov/cber/tissue/ovrstOlOl.pdf> (last visited Feb 17, 2006) ("It is esti-
mated that tissue banks distributed more than 750,000 [cadaveric] allograffs for trans-
plantation in 1999.").
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value in research laboratories, commercial biotechnology supply
companies, and human beings." 5 The expanded exploitation of
human tissues and organs necessitates our study of their legal
and social status °.3 6 Absent clear legal definition, the status of
body parts is shaped by sporadic, inconsistent judicial analysis,
which is woefully unmindful of the rapidly expanding, unregu-
lated biotechnological terrain.
In Moore, Justice Arabian's concurrence reveals that the
court's trepidation about granting the body a legal status was
less grounded in the task of setting a value on the cell line or es-
tablishing its legal status. Rather, the potential denigration of
personhood was his chief concern. Arguably the California Su-
preme Court took the path of least resistance by adopting a hold-
ing that recognized only a breach of fiduciary duty, but nothing
more. By doing so, the court abrogated its responsibility to re-
spond to factors exogenous to stare decisis. The difficulty for ag-
grieved plaintiffs is that in the absence of legislative guidance or
any clear precedent on body part theft or fraud, they are left to
rely on a constrained judiciary. The court's formalism is demon-
strated by the majority's exclusive reliance on legislative enact-
ments and the common law.30 7 Absent guidance, the majority was
unwilling to think as creatively as Dr. Golde and the other de-
fendants about Moore's cell line.
Sadly, a poor example is made of the law when courts fail to
engage in the dirty but necessary business of tussling, explain-
ing, and deeply engaging with the law, with the ultimate objec-
tive being to do what is right and fair. Arbitrarily distinguishing
entitlement to body parts based on the status of the possessor is
but one example of the departure from the robust, thoughtful,
and engaged approach of "judging" done by Traynor, Hand, and
Cardozo. The Honorable Mary M. Schroeder laments the loss of
that type of judicial rule-making.0 ' She describes how Cardozo
not only canvassed prior decisions of his court, but also discussed
reasons why the providers of products are held to have a "duty of
305 See Goodwin, Commerce in Cadavers, LA Times B15 (cited in note 16).
306 See, for example, Gwen Mayes, A Rose by Any other Name: Finding a Suitable
Definition of Body Parts for Legal Purposes-A Legal Commentary, Transplant News (Dec
9, 2002) (explaining that biotechnological advances has changed the way individuals view
themselves: we are more protective of our bodies and our right of privacy).
307 See Moore, 793 P2d at 489 ("[F]irst, no reported judicial decision supports Moore's
claim, either directly or by close analogy. Second, California statutory law drastically
limits any continuing interest of a patient in excised cells.").
308 See Schroeder, 1994 Wis L Rev at 14 (cited in note 128).
THE UNIVERSITY OF CHICAGO LEGAL FORUM
care toward people other than the primary purchaser."3 °9 In a
case involving the manufacture of an automobile with a defective
wheel, she notes, "Cardozo ... determined that the same princi-
ples of liability that applied to the producers of dangerous prod-
ucts should apply to a manufacturer of a defective car, even
though the car itself may not have been inherently dangerous."310
In effect, she notes, "Cardozo took the law out of the horse and
Y) 311buggy age.
By contrast, contemporary rule-making encumbers the very
pitfalls Schroeder warns against. She scolds the bench, "we defer
... we are preoccupied with applying the proper 'standard of re-
view,' ... we avoid deciding whether there was a legal violation by
discarding the question."31 2 This type of rule-making disservices
all litigants, particularly patients and research subjects, by leav-
ing them vulnerable to the thirsty grasps of researchers, physi-
cians, universities, and tissue banks.
When courts fail to engage with those who seek the halls of
justice for a fair and informed deliberation and redress, the law
is perverted. Here too, in the expansive biotech age, judges must
take the law out of the horse and buggy age. Thus a discourse
about naming the body's legal status is hardly a frivolous pur-
suit. Its legitimacy is derived from the fact that we lack a no-
menclature to fully assess, refer to, and describe the status of the
body, leaving a robust industry with a spider-like reach to per-
form that legislative or judicial task.
309 Id.
310 Id at 14-15.
311 Id at 15.
312 Schroeder, 1994 Wis L Rev at 10 (cited in note 128).
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